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ABSTRACT
Alpha (a )-adrenergic agon ists represent a novel drug class of spinal
analges ics and are most COf'MlOI'lly used in combination with local anesthetics
and opioi ds. Spinal noradrenergic ant inodception is mediated primari ly by a 2-
adren oceptors, although 0 l-adrenoceptor-mediated ennnoclceptlon has never
been disprov en. As demonstrated vasoconstJictors. however, there are
concerns rega rding the safety of the spinal administrat ion of 0 1- and 0 2-
agon ists . alone and in combination.
The pupose of thi s study was to determ ine if intrathecal (i.t)
methoxamine (MX) (a C"agonis t) potentiates i.t. dexmedet omidine (OX) (a z-
agonist)-i nduced antinociception . if l.t, Ox.. alone and in combination with MX,
inject ed twice dai ly for fo..r days, causes spinal neurotoxicity , and the effect of a
sub-tox ic combination of Lt. OX and MX on Lt. dynorphin-induced neuro toxicity.
Male, Sprag ue-Oawley rats (300-400g) implanted with i.L catheters (l l
terminat ion ) were used throoghoot.. The i.t i~eclion of dexmedetomidine (0.01.1
1J9) produced dose-dependent antinocicepti on in the tail flick (TF) and paw
pressure (PP) tests (EOso= 45 and 252 ng, respect ive ly). The add ition of a fixed
dose of MX (10 ).lg i.t), which produced <5% maximum percent effect (MPE) in
the TF test and was inactive in the PP test, significantl y shifted the OX dose
respon se ccve to the left (EOso= 8.1 n9; TF test and 10 ng; PP test) but did not
prolong OX's duration of action. A fixed dose combinatio n of OX (0.025 1J9) +
MX(10 1J9)producing near maximal antinociception in the TF test and
intermed iate aet ivlty in the PP test, was near comp letely blocked by prazos in (10
IJ9 u.) or W yeth 27127 (0.51J9 i.t).
Repea ted Lt. injections of high dose OX (10 IJg) and OX+MX (10 IJg each)
produced sedation but no motor dysfunction. no inflammation . haemorrhage or
necrosis of the spina l cord . Immunoh istochemical studies revealed no damage
to or loss of calci tonin-gene-related peptide immunoreactivity(CG RP-IR) in either
the dorsal or ventral horns or substance P immunoreactiv ity (SP-IR) in the
ventral hom as compared to veh ide-treated rats. In contrast , dynorphi n A,.13
(192 IJQ;120 nmol) produced: 1) immediate and irreversible hindlimb para lysis ; 2)
loss of the stepping and tai l flick reflex es; and 3) delayed bladd er and bowe l
dysfunction. Forty-eight hours after dynorphin, immunoh istochemical
examination revea led a marked dep letion of CGRP-IR motor neurons in the
lumbar ventral hom. CGRP-or SP-IR was und"langed in the dorsal hom.
To assess the effect of Lt. OX and MX, alone and in combination, on
dynorph in neurotoxicity , rats were pretr eated with Lt.Ox. MX. a combination of
OX+MX (10 IJQeach ) or saline 15 min before Lt. dynorphin A,.13(1921J9:12O
nmol). In saline pretreated rats, dynorphin produced the same effects as
described above. Pretreatment with i.t. Ox. MX or OX+MX attenuated the
hindl imb paralytic effect of dyn orph in. Twenty..four holXS after inject ion. motor
iii
reflexes were preserved and accelerating rotarod (RR) scores were similar to
controls (no dynorphi n) in 4 out of 5 OX-, 3 out of 5 MX- pretreated and 4 out of
4 OX+MX-pretreated rats. Histological evaluation of the spinal con::Is obtained
from these rats were cons istent with these functional results , indicative of a
neuroprotective effect. For OX and DX+MX pretreated rats , there was a
corresponding decrease in rectal temperature (up to 3.4°C for OX alone). MX
did not alter rectal temperabse. These results of this study indicate that 1) a
threshold dose of i.t. MX potentiates a z-rnediated antinociception in the rat; 2)
repeated spinal administration of this drug combination has no detectable
neurotoxic effect and 3) pretreatment with these drugs effects neuroprotection
against Lt. dynOrphin in the rat.
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1.0 INTROOUCTION
1.1 Statement of the Research Problem
With the elucidation of pontospinal noradrenergic pathways as components
of the 'endogenous pain control system', and the subsequent pharmacological
characteriza tion of the adrenoceptor subtypes modu lating nociceptive transmi ssion
in the spina l cord. it was qu ickly realized that a-agonists might exert a direct
antinoci ceptive/analgesic effect. Indeed , the intratheca l (i.t.) admin istration of
agonis ts with selectiv ity for Q 2-adrenoceptors was shown to produce a dose--
dependent, behavioually~efined elevation of nocicep tive threshold in a variety of
experimental animals. Important ly, th is antinociceptive effect occurs without
demonstratab le motor effects (Kuraishi at al., 1979; Reddy at al.• 1980; Yak$h and
Reddy, 1981; How e et at . 1983). In contrast, doses of o ,-agonists necessary to
achieve antinociception in the rat produc:e<l concurrent hyperr eflexia. cloni c flexion
of the h ind limbs and serpent ine movements of the ta il (HO'Neat at , 1983). The
failure of i.t a 1-agonists to discriminate between sen sory and motor effects has
been used as evidence against the role of a 1-adrenoceptors in spinal
antinociceptiorvanaJgesia. However, the contribution Ofthis a -receptor subtype has
never been disproven. If mJ ltiple a-a drenoceptor subtypes effed antinociception,
then the co-administration of a l - and a 2-agonists in threshold or sub-threshold
doses should yield additive or potentiall y supra~addjtive ennnocrcepnon This
pharm aco logical interad ion has not been investigated.
Whi le segmental and prolonged analgesia can be achieved with perispinal
aug administration, ttWs tectnicJ,Je carries with it an increased risk of drug4nduced
neur otoxicity. Experimental studies of selective drugs given epidurally or
intratheca lly to the rat have frequently noted an abrupt and sustained oecrease in
spinal cnrd b1oo.1 flow' prior to histopathological damage in the spina l ventra l hom.
Current evidence suggests that this neuroto xic effect arises from drug-induced
isdlemic injury . The pronounced vasoconstrictive effect of a 1- and a 2-agonists on
central blood vessels raises important quest ions about the ir safety as spinal
analgesics. especially'Mlen given in combination The safety d such a combination
alone, or in the presence of a known neurotoxin suc:tI as dynOrphin, has not been
assessed. 1he rationale for such an investigation lies in the increasi ng popularity
of 'balanced anesthesi a' in which a mixture of phannaco logica l agen ts. including
a-agonists , with varying receptor select ivities, medlanisms eXaction and adverse
effecr:s, are co-administered to achieve more effective d inical anes thesia\analgesia.
In the present study, the effect of i.t methoxamine (MX; a 1-agonist) on
!hennal (tai l fl ick; TF) and mechan ical (paw pressure ; PP) antinociception elicited
by i.t. dexmedetomidine (OX; Q 2-agonist) was first investiga ted in the rat. A sub-
acute neuro toxicolog ical assessment using behavioura l. morpholog ical and
immunohistochemical indices was subsequently undertaken to investigate the
safety of this drug combinat ion. Lastly, the effect of this combination on l.t.
dynorphin-induced neurotoxi city was determined .
1.2 aooAgonisls as Adjuvants to Loeal Anaesthetics
The spinal administrat ion of a local anaesthetic for the purpose of surgery
was firs t attempted in Gennany in 1899 (Bier, 1899). Bier had noted the success
of reg ional coca ine anaesthesia in lowering the requi rement for general
anaesthesi a but he recog nized the limitations of regional anesthesia for major
surgical operations. In order to -render large areas of the body insens ible to pai n-,
Bier injected coca ine intratheCally in doses ranging from 5 to 15 milligrams (mg) .
A level of anaesthesia sufficient to allow major surgery was achieved in all six
pat ients
The use of epinephrine , a non-selective adrenergic agonist, to prolong spina l
anaesthesia was introduceddinicaJIy in 1900 (Braun, 1914). Braun, Bier and other
contemporaryGerman d inicians began us ing ep ineptrine to prolong the dura tion
of actio n of 1.1. coca ine, thus obviat ing a significant disadvantage of spinal
anaes thesia (Bier and Donitz, 1904 ; Heinke and Lawen, 1905; Braun, 1914).
Bet"Neen 1900 ancl 1940, the use of epinephrine with spina l anaesthesics enjoyed
spo radic popularity but did not attain common acceptance becau se of an earl y
report tha t Lt. epinep hrine caused pronounced ischemia in the spina l cord of
experimental animals (Biberfield, 1907). Using experimental animals under
contro lled conditio ns, Prickett , Gross and Cullen (1945) demon strated that the
addition of 1:10,000 and 1:30,000 (0.1mgJmL and 0.03 mglmL) epineptvine could
pro long the anaesthesic effect of i.t. procaine without permanent damage to
nervous tissue. This study stimulated the re-inYestJgatio of this techn ique . Inc:Ieed,
recent clinical studies have shOwn that the add ition of ep inephrine (0.1 to 0.3 mg)
prolongs the dura tion of action of spinal bupfvaca ine, lidocai ne or tetracaine from
15 to 44% in patients undergoing abdomina l. hip or electi ve surgery of the lower
extremities (Leicht et al ., 1966; Raele et al., 1987; Momose et aI., 1994) . In this
regard. epineptvYle is believed to counteract the arteriolar vasodil at ion ind uced by
local anaesthetics in the spinal cord, thereby de laying absorption and ina-easing
the residence time of the local anaesthetic near the site of injection . Indeed,
epneptvine is a pat en: constrictor of cerebral (LoP acin and Rudy, 1983 ) and spinal
(Partridge. 199 1) blood vessels . Whether this pro longat ion is truly a
pha rmacokine tic interact ion or an independ ent pnarmecodynamic ettect of
epineptYine (see section 1.3) remains controv ersial (Fink et al ., 1978; Denson at
aI., 1982, 1983. 1984; Ravindran et al.,1983). However, it is noteworthy that non-
select ive adrenerg ic (norep inephri ne), a 1-selecli ve (pheny lephrine) and a2~
selective (donidine) agonists have also pro ven eff ective in prolongi ng the duration
of sp inal anaesthes ia (Mens ink et al., 1987; Racle et al .• 1987; Kishikawa et aI.,
1993 ; Fukuda et aI., 1994 ).
1.3 Spinal Pharmacology of a -Adrenerg ic Antinoclceptlon
Noradrenal ine (NA). re leased from bulbo spinal neu rons during exposure to
noxious stimuli, is an important med iator of the endogenous pain cont rol system.
Thus. focal stimulation of the rat locus coerureus (l CI. a major source d
descending noradrenerg ic neuron s, was shown to inhibit noxious evoked: a)
neu-onal activity in the dorsa l hom (Jones and Gebha rt. 198Gb); b) spina l reflexes
(Jones and Gebhart. 1986a: Janss et at , 1987) and c) comptex nocif ensive
behaviours (Segal and Sandberg, 1977: Sandberg and Segal, 1978; Marga lit and
Sega l. 1979 ). The concentration of NA and the NA metabol ite. 3-methoxy4-
hydroxy..phenethylgycol was also significantly ina-eased in CSF following electrica l
stimulation of the LC (Crawley et al., 1979). The l.t. administra tion of a -
ad'enocepta antagonists slgnificanUy blocked the antinociceptive effect el icited by
l C ad ivation, suggesting a spinal site of antinocice ption (Jones and Gebhart,
1986 a). Among the series of pharmacological antagonists used (phentolamine,
yohimbine, prazosin. naloxone , methtysergide, atropine and biOJCUlline). only the
non-selective c-eoteecnrst phen tolamine, or the oJ-selectiv e antagonist.
yohimbine. significantly blocked the inc:tease in nociceptive thresho ld el icited by LC
st imulat ion. Similar resu lts were reported by Miller and Proudfi t (1990) .
These ear1y studies of endogenous pain modulation led researchers to
examine the effect of exogenous NA and other a-agonists. VVhen injected i.t. , NA
produced a sig'lificant dose-dependent irx:rease in response latency in the hot plate
and lail flick tests (Reddy and Yaksh, 1980; Reddy et al., 1980: Howe et at , 1983):
an effect reproduced by other adrenerg ic agonists including OL-a -
methylnorepinephrine; DL-epinephrine . ST-91. cicnidme , L-phenylephrine, 3-4-
dihydro xytolazoline. oxymetazol ine. methoxamine and cirazoli ne (Reddy et at.
1980; Reddy and Yaksh, 1980. Howe and Yaksh, 1982a,b; Howe et ar.. 19B3). ~
Agonists. such as isoproterencl . were without effect even at very high Lt. doses
(Reddy at aI., 1980) .
While the U. administration of either a ,- or a 2..adrenoceptor agonists
increased l'llJOceptive ttYeshoIds in the rat, the doses of a ,-agonists necessary to
achiev e this effect produced conwrrent dose-dependent motor effects such as
hyperreflexia, clonic flexion of the hindlimbs and serpentine movements of the lail
(Howe at at . 1983) . In contrast, antinociceptive doses of either non-selective a -
agon ists or a 2-seledive agonists inhibited nociceptive beha viours without
demonstratable motor effects (Reddy et at. 1980; Reddy and Yaksh . 1980; Howe
at al., 1983) . largely. on the basis of these observations . and on the variable
effects of a ,..agonists on dorsal hom neurons, it was concluded that spinal
noradrenergicantinociception is mediated by a 2-adrenocept ors. In support of this
dai m, adrenergic agonists with the greatest a 2\a, receptor select ivity (e.g. OX) are
the most effective in acute antinoclceplive tests (fakano and Yaksh, 1993).
Nevertheless, the contribution of a ,-adrenoceptors in spinal adrenergic
antinociceptionlanalgesia has never been disproven.
Early experiments demonstrated that a ,-selective agonists do effect
antinociception following both systemic (Bentley et et., 1983; Hayes et al.• 1986)
and spinal administration (Howe et at , 1983; Yaksh, 1985). In tum,
ph a nnacologi ca l studies of NA-ind uced therma l antinociception , showed that the
that o, -antagon ist. prazosin, was more effective than ~-antagonists in inhi biting
the antinociceptive effects of i t NA (Reddy et at. 1980; Howe et a l., 1983). The se
data are suppo rted by the results of rad iol igand binding stud ies an d quanti tat ive
autoradiography demonstrating the presence of o ,-actrenoceptors ttvoughout the
dorsal grey matt er of the rat spinal cord (Giron et at. 1985 ; Simmon and Jones ,
1988 ; Roud et et al., 1993). and are consistent with the hypo the sis tha t spina l a l -
adrenoceptors mediate at least some component of nor adrenergic antinociception
in the rat.
If both a ,- and 0 2-adrenergic receptors effect spinal enuncciception through
distind eff ect or mecha nisms, then co-administra tion of an a , -agoni st and an Oz·
agon ist in threshold or Slb-ttreshold doses would be expected to yie ld an additive
or potentially a supra..addit ive ant inociceptive effect. Such an in teraction in VIVo
wo uld be consistent with the non-selectrve nature of NA as an agonist at a-
adrenoceptors .
1.4 Neuroto xic ity of Sp in ally Ad minist ered Drugs
As the practice rAspinal Malgesia has grown , there has been an incr easing
appr eciat ion of the potential for adverse effects with th is technique and the need
fo r systematic neuro toxico log ica l evaluation of drugs intended for sp inal
administration . Th is has proven to be part icu larfy impo rtant for peptide drugs. For
example, 100 ~ of Lt. somatostatin, a cyclic tetradecapeptide thought to be
Involved in the spinal processing of nociceptive informatton, produced severe hind
limb dysti.n:;tion in the rat, up to the time of saaffice 6 days later. There was also
a correspondi ng loss of sensitiv ity to thermal and mechanical nociceptive stimuli.
Histological (light miaosaJPY ) examination of the spinal cords removed from these
an imals revealed mild to severe nudeotysis of ventra l and dorsal ho m neurons with
localized inflammation (Gaumann and Yaksh, 1988). Similarty, pept ide analogues
of substance P (developed as putative neurokinin receptor antagon ists) given i.t,
induced bilateral motor blockade in the hind limbs, and widespread neuronal
necrosis in the lumbar region c:A the rat spinal cord (Post and Paulsson. 1985;
Freedman et at , 1989). Comparable outcomes have been reported with i.t.
endothe lin (HOkfelt et at, 1989), an endotheli~erived vasoconstrict or peptide
(Yanag isawa et at . 1988), Lt. dynorph in A, an endogenous kappa opioid agonist
(Fa den and Jacobs, 1984 ; Herman and Goldstein, 1985; Spampinato and
Oand etettl, 1985; l ong et at . 1988; Stewart and Isaac. 1989 ) and arginine' ·
vasopressin (long et at, 1989b). Table 1 summarizes the neurotoxico logical
resu lts with these peptides.
Although the exact IT'lE!d'la'lisms ISldertying this neurotoxicity remain unclear,
these studies demonstrate : a) the severe and often irreversible damage that can
OCOJ( in the spinal cord after the local administration of biological ly active agents,
induding those found endogenously in neurons of the spinal cord ; and b) the need
for careful toxicological evaluat ion of drugs intended for spinal use.
Table I
Studiesof SpinalNeurotoxicity FollowingIntrathecalAdministration of Peptides in the Rat.
Drug! no.. Tests Histology(Lisht or Immuno-) SpinalNeurotoxicity
Reference
Somatostatin 10, 30 and 100 AN, 6 days after injection: 100~g: temporaryor permanent·
(SST) /
.8 auto- 30 ~g SST: mildinflammatory hindlimb motor dysfunction with flaccid
Oaumannand nomic response in4/5 ralS paralysisin most severecases.25% ohats
Yak.h(1988) and 100~g SST: mild or severe died 10min. within injcction.
motor nucleolysis ofventral anddorsal • permanent - up to day 6 when rats were
func- horns in the presenceof sacrificed and perfused
tion inflammatory reaction
Spanlidel 2.8 1,2, and3 days after injection: Bilateralmotor blockadeof the hindlimb.
Freedmanet at , no CGRP·IR inmotoneurons, that did not recover up to timeof
(1989) cresylvioletstaining indicateda perfusion(1,2or 3 day. after injection)
completeabsenceof
motoneurons anda marked
gliosis
DPDTand 2.8 AN 3 days aftcr injcction At half· maximaldose( I~g). all animals
DADTUPost extensivenecrosi, of neuronal showedmotor weaknessof the hindlimb,
andPaulsson bodies in the ventralanddorsal At 2 ~g. all animal, hadpronounced
(1985) horns motor impainnent of the hindlimbs and
non-responsiveness in the tail flickor
pinchingofhindlcgs. Thispersistedup to
timeof perfusion, 3 dayslater.
s
TableI (cont'd)
Drug! Do.. Tests Hislology (Lightor Immuno-) SpinalNeurotolcic:ity
Reference
EndolhelinJ 0.03 ~s or 0.1 24 h after injeclion: 0.03 ~s : Allrau showedcompleteparesil
HOkfelt et u,
.8 Fullyparetic rats showeda afterS min. All but one showed full
(1989) marlc.ed 10 51 o(CGRP-lRin recoveryat 3 h. Theonerat remained
moroneerora in(he ventralhom paralytic unlil perfu.ion.
at thetip o( lheeetheter, Sinsle 0.1 .,,8: 3/S rals died, 2 within S min., last
motoneurons appeared rounded within 3 h. SurvivinS rals showed
withoutdeodritic processes. complete parest. until perfusion, 24h
later.
Arginine'· O.S· 1000pmol AN No hislochemicaldifference Dose-related loISof motorfunction in
vasopressin I HD betweencontroland hindlimbs. Someratsdied withinS-10
Longera1.• experimentalanimals min. of peptideinjection due to pulmonary
(198%) edema. Rats recovered hindlimb function
within30min. ofinjection,evenwith 1.0
nmoldole . Flaccid hindlimb paralysis was
eccompenied bylossof flexor or vocal
responses to pinching of thehindlimbsor
tail.
Dynorphin AI 12.5 and25 AN 25 nmol producedhindlimbparalysis and
Spampinatoand amol tail flaccidity laslinsscveralhours.
Candelel1i
(1985)
::
Table I (cont'd)
Drug! Dose Tests Histology (Light or Immuno-) Spinal Neurotoxicity
Reference
Dynorphinl 14 nmol or Long-lastinghindlimbparalysis (hindlimb
Herman and greater and tail flaccidity)
Goldstein 14 nrnol: paralysis woreoff in2 h
(1985) 20 nmol: paralysis lasted forat leastone
week
50 nmcl: paralysis lasted for at least one
week
Dynorphinl Dyn( I-17) : Allpeptidesproduced dose-relatedflaccid
Fadenand 30omol; hindlimb paralysis with the orderof
Jacobs (1984) Dyn (1-13): potency being DYN (1-17) > Dyn (1-13)
10,30,50 or 100 > a NA .. Dyn (1-8) . Spontaneously
omol reversible overa 48 h period. However,
Dyn( I-8): at highdoses (50 omol), 1/3 of the animals
30,50 or 100 developed paralysisthat was irreversible.
nmcl,
e-neo-
endorphin:
30,50 or 100
nmol
;;;
Table I (cont'd)
Drug! Do" Tests Histology(Light or Immuno-} Spinal Neurotollicity
Reference
DynorphinAI Dyn A(I-I) · AN DynA(I-1)25 nmol: Severe Oyn A(t- IJ) : Dose-relatedlou of motor
Lcng et el., J. I-50 nmol andextensive neuronal injury function in hindlimbs and tail, loss of
(1988) Dyn A()- I) : throogout the lumbosacral flexoror vocal responses 10 pinching of
14 ·56 nmol enlargement . hindlimbs. Motor dysfunction ranged from
transient, mildparaparesis to persistent.
flaccid paralysis of hindlimbs and tail
Recovery was also dose-related. wlrh low
doses (3.1 eod6.2 nmol), recovery
complete within 2 h. Slowerand more
limited recoverywith 12.5 and 25 nmol.
SOnmol: rlt l did not recover neurologic
function, flaccidityoccasionaly turned to
spasticity by4 to 7 days after injection.
These animals also had loss of nociceptive
responsiveness, hilldlimbedema, bowel
dysfunction, bladder distension with
infarctionand urinuy incontinence.
Oyn A(3- IJ) : At 28 and 56 nmol, rats
remained flaccidly paralyzed24 h later.
Abbreviations: AN, anlinociception; HO, hemodynamics; CORP-lit, calcitonin gene related peptide.inununoreactivity; DPDT (0 -
Pro' , O-Trp"' )-subslance P; DADTL(D_Argl , D_Trp7·'). substance P (spantide)
'"
,.
1.5 Patho phys iology of I.T. PeptidtHnd uced Neurotoxicity
In experimental studies examining the spinal neurot oxic effects of dive rse
peptides such as dynorphi n and endoIheIin (see Tab le I), twogeneral observations
have been consistently reported. First, each peptide induces an abrupt and
sustained dea'ease in spina l cord blood flow (see Table II); an effect that precedes
all behavioural , morphological and ilTV11unoh istoc:hemical measures of spina l
neuro toxicity . second. cell necrosis occurs primari ly in motor neurons of the ventra l
horns. This latter observation is consist ent with the difference in blood supp ly to
ventra l as compared to the dors al hom s of the spinal cord (see Figur e 1A and B),
and the known vulnerability of ventral hom neurons to disruptions in spinal cord
blOOd flow (Cousins and Bridenbaug h, 1988). Indeed, prolonged aorti c cross-
crampi ng and the fai lure to re-establish the blood supp ly to the spinal cord is a
major risk fact or in the development of post-cpereuve paraplegia in patients
und ergoing aneurys m repair (Marini and Cunningha m, 1993).
Studies using radiolabelled mictospheres to quantitate ctalges in blood flow
have reported a decrease in the magnitude of spinal cord perfus ion following the
tt, inject ion of select ed neuro toxic peptid es (Helke et al., 1987 ; l ong et at , 1967;
Thomehill et al., 1969). Because this technique does not allow for the continuous
measurement of blood flow, the magn itude of change was assessed at time point s
cho sen arb itrarily after i.t drug administration. With the advent of laser dopp ler
technology, both the magnitUde and durat ion of change in spinal cord blood flow
could be followedin individualanimals.
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FIGURE 1
A. Arterial Supply to the Spinal Cord . The arterial supply to the spinal cord
originates from three main longitudinal syst ems: the ventral spinal artery and two
dorsal spinal arteries. These systems extend along the length of the entire cord
gMng 011 . series atbrancI1es that extend i1Io!he sp;naJ cord (centra l arte<y). Two
additiona l longitud inal arterial dlannels are found on the surface of the cord with
less frequency: the med ian dorsal spinal artery, situated at or dose to the dorsal
septum , and two lateral spinal arteries, situated about midway between the
attachm ent of the dors al and that of the ventral roots (Scramin, 1995). (Source:
Figure 7-10, Cou sins and Bridenbaugh , 1988 )
B. Blood Supply of the Spina l Cord, Horizontal Distribution. The "central"
area. suppfied only by the ventral spinal artery , is predominately a motor area . This
area is most vulnerable, since there is only one ventra l artery as opposed to the
dorsal spinal arteries of which there are two (only the left dorsal spinal artery is
dep ided). (Sotrce: Figure 8-10. Cous ins and Bridenbaugh, 1988 )
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As shown in Table II, somatostat in. spant ide, [D-Arg)-substance P,
endothelin, dynorphi n and arginine' -vasopressin all caused an immediat e decrease
in spinal cord blood flow folloNing i t administration . In the case of dynorphi n A (1.
13), the observed decrease in lumbosacral blood flow was also shown to be dose-
related (Long et al..1987) . Using laser doppler f1owmetry, Freedman at al., (1988)
~ that i.t somatostatin and spantide decreased blood flow to 16:t: 4% and 30
± 6% of cont rol , respecti vely . Thi s maximal effect OCOJrTed 10 to 20 min after
injection. Comparable reductions in lumbosacral blood flOW' toIkHiing i.t. [O-ArgJ-
spantide, dynorph in and AVP were reported using radiola belle d micros phere s at
simitar time points (Helke at at. 1987; Long et at, 1987; Long etal.• 1989a ). The
rapid onset of this hemodynamic effect was indicated by deaeases of up to 50%
of control two min after l.t, dynorphin A (1- 13) (Thomehill et at., 1989).
In the case d somatostatin and spartide, a gradual but incomplete recov ery
of spinal cord blood flow was observed 60 min after injection (60 t 14% and 53 t
20% of the pre-iniedion base line values . respectively) (Freedman at at , 1988 ). In
contrast, i.l endothelin ind uced a greater than 50 % reduction in spinal cord blood
flow for at least 3 h (Westmark et al ., 1995) . In the only rad iolabell ed microsph ere
study that looked at durat ion, blood flow returned to pre-treatment values 60 min
after Lt. AVP (Long et aI., 1989a).
These hemodynamic stud ies, and the biological diversity of peptides
effect ing spinal neu rotoxicity, sugges t a common phys iological , rather than
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pharmacological or direct toxicological. mechanism. That neurotoxicity is the result
of an ischemic insult secondary to peptide-induced vasoconstriction in the spinal
cord is also supported by the following experimental studies. In the rat, transient
occlusion of the descending aorta suppling the spinal arteries prod uced behaviora l
and histopa thological changes qualita tively similar to those induced by i.t,
somatostatin, various substance P antagonists, dynorphin A and AVP (Marsal a and
Yaksh , 1994). Coadministra tion of the vasodilator hyd ralazine (1 IJffiOI i.t ) with a
para lyt ic dose of dynorphin A (20 Mlol i.t) blOCked both the ele vation in lact ic acid
concentration in spinal CSF and the neuropathological effect of dynorph in A
compared to vehicle + dynorphin A-treated controls (Lo ng et at., 1994 ). Lacti c aci d
is a by-product of anaerobic glyoo/ysis indicative of an isdlemic state. Pretreatment
with thry otropin-r ele asing hormo ne (2 mglkg i,v.), 15 min before and immediately
coo- to the i.t. injection of spa ntide, prevented both the spinal vasconstrictive and
neurotoxic effect of spant ide in the rat (Freedm an et at , 1988 ;1989). Similarly . the
selective v-recectcr antagonist [1-(P-mercapt cMl. ~dopentamethylene
prop'lonintc acid) 2- (CHne thyl) tyrosine}-AVP blocked the decrease in lumbosacral
perfusion (Long etal.•1989a)' and the neurotoxiceffed of i.t. AVP in the rat (Long
et at. 1989b). To test the possibility that dynocphin might have a dired. neurotoxic
I It is important to note that the V, receptor antagonist did not alter SCBF when
injected alone. This finding argues against a prominent role of endogenous AVP in the
normal regulation of SCBF. However. AVP may be important in certa in pathological
conditions associated with vasospasm. compromised blood flow and ischemia
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mechanism. Long exa mined the effect of dynorphin A on cultured spinal cord
neurons. Concentrations up to 1 mM did not alter the viability of these neurons in
vitro( Long etal. .1994).
Vasoconstriction perse is not automatically detrimental to tissue . However,
when such an event leads to a sustained imbalance between blood flow and
metabolic demand. cel lula" i1uYand necrosiscan OCCU". During normal perfus ion.
ox idative phosphoryiation generates adenos ine triphos phate (ATP), the major
energy source of the cell . In the absence of adequate oxygenat ion and/ or glucose
delivery , neu"OI'lS must resortto anaerobicglycolysis: an alternate and less efficient
means of energy production . As ATP stores are deple ted, vital energy-dependent
mechanis ms (i.e. ion pumps) are strained to maintain cell homeostasis. For
exarll)l e, it has been estimated that the ion gradients mainta ined by these pumps
uti lize 50 - 60% of the ATP supply (Vamucci . t 990) . As these pumps fai l and as
sodium ions accumulate intracell utarly. ischem ic neurons become susceptible to
depolarization. This , in tum, can lead to the aca.muIation of excitatory amino acids
(EM) and other neurotransmitters in the extracellu lar space of the ischemic field
(Shimizu at at , 1993 ; Ueda at at , 1993). Indeed . a neurotoxic dose of i.l dynorph in
A produced a four..fold and three-fold increase in the concentration of glutamate
and aspartate, respectively. in rat spinal CSF (Long et at, 1994 ). The EAA-evoked
influx of calcium through N-methyt-D.aspartate (NMDA)-gatad channels and SOCIilm
through kalnate - and (±}-a-amino-~ydroxy-5-melhy l isoxazol~-proprionic acid
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(AMPA)-gated chamels 010tr0w and Coyle, 1991) can f\.rther aggravate the
lIlStable conditions initiated by iscnemta The rapid influx of ion s may also cause
edema and lysis of the cell membrane. The sensit ivity of spinal neurons to EM
recep tor agonis ts has been demonstrated in vdro. NMDA. AMPA and ka inate
receptor agon ists eacn ind uced the concentrat ion-dependent death of aJltu red
muri ne spina l co rd neurons (Regan . 1996) .
Wi th in the normal cell , calcium is tightly regulated by a combina tion of
energy-dependent ion pumps and d irect binding to the endop lasmic rencalum .
Wh en the pumping mech an isms fail, intracellular stores of ca lciu m are re leased
thereby increasing calcium in the cytoso l ([Cal) to abnOrmally high
concentrations. In fact.the (Ca' is inversely related to ATP concentration duri ng
periods of AT? depletion and resynthesis (Kim-Lee at al. 1993). Such a rise in
[Ca" can have serious metaboI icc:onsequences for the cell (see re view by Krause
el aI., 1988 ). The activ ation of phospholi pase ~. triggered by a rise in (Ca-.J.
initiates the arachidon ic cascade. Prostaglandi ns, Ihromboxanes and leukotr ienes
arising from this pathway trigger the prod uction of oxygen free radica ls that have
been implicated in lipid peroxidation and nucle ic acid damage (Traystman et at ,
1991). The activa tion of calcium-dependent nuclea ses can result in direct lethal
injury to the cell 's DNA (Tullis et at.. 1982). Wi thin seconds of the onset of
ischemia, a calcium-depe ndent, proteolyt ic enzyme converts xanth ine
dehydrogenase from the -0" (NAD-reducing form) to the -0 · oxidase torm (McCo rd
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et at , 1985). Upo n repertueton. the "0· form of this enzyme uses two produ cts of
ATP degrada tion, hypoxa nthine ~ xanth ine. and oxygen to produce a toxic
~ radical (0 21. Of ecorse , the inability to regulate [Ca' will also promote
the further release of EAA's (Figure 2) .
AIthoU';tlOU" trlderstanding r:I the medlanisms of neura l injury triggered by
ische mia has grown consi derably, the number and complex ity of events fo llowing
ischemia has made elucida tion of the exact sequence of events difficu lt
Nevertheless, it is dear that anyth ing that COfl1lI'O'"ises spinal cord blood flow , such
as the i.t. inject ion of the pepudes discu ssed above , has the potential to effect
spinal rle\XOtOxicity, especially in marg ina lly perfused regions like the ventral hom.
Ischemia- IATP- Cl+Ove~oad in Cytosol
Activate
phospholipases
Activate nucleases
Conversion 01XD-XO
Release01excitatory
neurotransmitters
I j
Figure 2 Proposed cycle of lscnerma-medlat ed neurotoxicity.
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Table 2
Studies of Spinal Cord BloodFlow Following Intrathecal Administration of Peptides inthe Rat.
\i
Drug! Do", Techniquefor Changein Spinal Cord Blood Flow TimeCourse
Reference Measuring
BloodFlow
Somatostalin 30 llg laser doppler Blood flowdecreased immedialely At 60 min. blood flow returned to 60
(SST) /Freedman after injection. The maximum :t.14 % of the pre-injection baseline
ctal. , (I988) reduction of 16:1: 4 'I. of the pre- value.
injection baseline value occurredal
10 min.
SpantideJ 2 .8 laser doppler Blood flow dropped immedtetely There was a gradual but Incomplete
Freedman et aI., after injection and al 20 min was recoveryof spinal cord blood flow.
(1988) 30:1:6% of the pre-injection At 60 min, blood flow was 53± 20
beseline velue. % ofthe pre-injection baseline value.
0 .ArgI.0 .Pr02• 3.J nmol radiolabelled Blood flow decreased41% in the
o-T rp"' , Leu". micrcspheres thoracic and 17 % inlhe
substanceP([D· (reference lumbose&ral spinalcord, IS10 20
Argl·SP)/Heike sampling minafter injection.
et el., (1987) method)
AVPI 1,1 0, SO radiolabelled Al lOmin afteri njection, AVP Lumbosacral blood flow remained
Lcng et al., and 100 microspheres reduced lumbosacral blood flow significantlydecreased30 min after
(l 989a) pmol (reference from 37 10 87 % with doses of 10 the 100 pmol dose. Recovery 10
sampling and lOa pmol, respectively. pre-treatment levels occurred by 60
method) min.
Table 2 (com'd)
~
DN g/ Do" Technique for Change in SpinalCord BloodFlow Time Course
Reference Measuring
Blood Flow
Endothelinl O.31 mM laser doppler The decrease was rapid in onset A greater than SO% reduction in
Weslmark et et., achievinga greater than 500/0 bloodflow wasmaintainedfor at
(199' ) reduction frombaseline. least J h when the animal was
anesthetised and perfused for light
microscopic examination of the
spinal cord.
DynA (I-IJ) 20 nmol radioillbelled Two miretes after injection, blood t
Thornehitl et al, micospheres flow wasdecreasedby up 10 SO%
(1989) (reference in segments 2 em caudal and I cm
sampling rostral to the tip of thecatheter.
method)
Dyn A( I. I3) and DynA( I- radiolabelled DynA (I· 13):Dose-related
DynA () -lJ )I 13): 12.5, microspheres reductions in lumbosacral blood
Long er el., 25 and 50 flow, Lumbosacral blood flow
(1987) nmol was decreased )] · 75 0/.and
DynA (3. thoracic blood flow was decreased
IJ ), ' 0 380/. at 10min post-lniecrion..
nmol Dyn A (3-13): There was an
approximately40 % decrease in
lumbosacral blood flow 10 min
afterinjection.
Abbreviations: i.t., inuathecal; Dyn, dynorphin; AVP.arginine "-vasopressin
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1.6 The Vascular Effects of a - Agon ists
In light of the presumed mechanism of toxicity of i.t, peptides desetibed
above , and the the fad that perispinal routes of administration can expose the
spinal cord to concentrated drug solutions (mM ran ge), it is importa nt to note that
both a ,• and Q 2-adrenergic agonists are potent constrictors of central blood
vessels . In a study using isolated cerebral arteries from the monkey . phenylephrine
and norad renali ne produced a dose-dependent contraction of vaSOJlar smooth
muscle (Tod a. 1983). The maximum responses were comparable for both drugs
although the ED50 of phenylephrine (1.11 %0.41 X ,Q"l' M) was 5.6 times greater
than that of norepinephrine. Although , NA is a non-selective a -agonist, the
contractions induced by NA using isolated human and monkey cerebral arteries
appear to be mediated by c ,-receptors. Treatment with prazos in (3 X 10-'0and ' cr-
M) signiflC8ntly attenuated the contractile response to NA (10""' to 10-&M) .
Yohimb ine was without effect in concentrations up to 10"' M (Tode, 1963).
CougNan et al. (1992) showed that isolat ed canine middle cerebral arteries exhibi t
dose-related contractions to the highly selective a 2· agonist , dexmedel omidine (OX;
a 2 to a. ratio of 1620 :1 versus 200 :1 for donidine; Virtane n et aI., 1988 ). At a
concentra tion of 3 X 1~ M, the max imum concentration of OX that could be used
without detectable a 1-mediated vasoconstrictia OX inc1Jceda response equivalent
to 72 .8 ± 5.7% of the max ima l effect evoked by 40 mM KCI.
Large systemic doses of a-agonists can cause cerebra l vasoconstriction..
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For example. 'ZJ::JtroN et a!. (1990 ) demonstrated a 45% cecreese in cerebral blood
flaw in isoflurane-anesthetized dogs following a systemic dose of OX (10 ~g i.v.).
Kartsson et aI. (1990) also demonstrated a 34% deaease in cerebra l blood flow in
halothane-anesthetized dogs using an identical dose of OX. The spinal
admi nistration of 0 , • or a 2.-agonists also impai rs spina l cord blood flow.
P!lenyleplYine (0.3. 0.5%). ......00 .,., the Io.m>ar subaracl1noid space of the dog.
decreased blood flow by 28% and 44%. respectively, 30 minutes after drug
administration (Oohi at at, 1984). In the rat, doses of 20. 100 and 400 nmol of i.t
donidine each reduced SCBF 15 min after inject ion. but gray and white matter
responded differently. In the grey matter of the spinal co rd. the largest decre ases
occurred with the 20 and 100 rmot doses (29 - 44% compared to control ). The 400
nmof dose produced significantdeaeases oI a lesser magnitude (12 - 27%). In the
white matter, the 100 and 400 nmol doses produced reduct ions of 17 - 39%, whi le
the 20 nmol dose was wrthout effect (Cro sby et at, 1990 ). Epi dural donidine (10
and 30 !J9/kg) also affected spin al cord blood flow (SCBF) in the pig (Gordh at al .,
1986a). Reduct ions of 25 % to 35% were observed in the lumbar and thora cic
segments 45 minutes after drug adm inistrati on . The se data clearly indi ca te that c-
adrenergic agon ists can impa ir blOOd flow through cere bral and spin al vessels.
A direct co mparison of the hemodynamic effect of neurotox ic peptides with
that of a -agonists is compl icated by the use of the different me thodologies, speci es
and spinat routes of drug administration. Nevertheless, both classes of drugs have
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been shown to deaease spinal cord blood flow to a comparable deg ree with in the
first 30 min of l.t, drug administration. The 25-35% decrease in blood flow reco rded
45 min after epidxaI donidine (Gordh et al.,1986a) suggests that a-agonists have
a sustained effect . and that they may induce a substantial d isturba nce in spinal
perfusion. Unfortunately. there are no nme-cocrse data by which to judge the
actual dura tion of this disturbance.
The adrenergic nerve supply to most blood vessels ori gi nates in the pre- or
para -ve rtebra l gang lia of the sympathetic nervous system . In the brain. the
innervati on of some blood vessel s may originate from central catecholaminergic
neurons (Edv insson at aI., 1973) . There is great varia tion in the pattern and den sity
of the sympathetic imervation of vascne- smooth muscle (Bumstock, 1975). Large
elastic arteries generall y show a sparse pattern of innerv ation while capillaries.
venutes and small veins have virtually no adrenergic nerve supply . In contrast ,
smaller arteries display an ncreased dens ity of imervation. The y are SlI'TOUnd ed
by a hair~ike net'Nork of sympathetic postgang lioni c nerve fibers infl uenci ng smooth
muscle ce lls. Indeed , each termina l branch of a postganglionic fiber courses across
the surface of one or more vaSOJlar smooth musde ce lls. re leas ing no repineptrine
fro m the vesicles with in its multi ple vancoeftes.
Vasoconstriction is med iated by post-junctiona t 0 1· and o ,-adrenoceptors.
Whereas larger aterio les and venutes are regu lated by both °1• and o z·
ad renoceptors , vasoconstriction in the tenn inal vessels is medi ated prim ar ily by 0,·
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adrenoceptors (Faber , 1988 ). a ,-Adrenoceptor mediated contraction of smooth
muscle relies on the release of intrace llular, rather than on extracellu lar, stores of
Ca'". Thus. agonist occupati on of vascular o r-adrenoceptors activates
pho sphol ipase C wh ich acts on phosphotidyl inosito l bisphosphate, a membrane
phospholipid, to produce two second messengers. Inositol triphosphate (IPJ is
refeased into the cytosol . and d iac:ytglycerol (OAG) remains in the membrane and
activates protein kinase C (PKC). IP~ evokes release of Ca- from intemal stores
withi n the saaopIasmic reticuIun of the muscle cell; PKC sensitizes the contractile
apparatus to Ca" . The net effect of a r-adrenoceptor activation is contract ion of
vescner smooth muscle without the movement of ions across the cell membrane
and with a min imal change in the membra ne potentia l.
The contraction of vascular smooth muscle mediated by 02-adrenocep tors
depen ds almost totally on extrace llular ea- and an increase in the membrane
permeability to this ion. It has been proposed tha t a 2.-adrenoceptor activation may
be coupled. via a pertu ssis toxin-sensitive G - protein (GJ • to phospholipid
hydrolysis involving phospho lipase 0 (PLO) and the fonnation of phosphatidic acid
(Abu1 0 et at. 1995). Once formed. phosphatidic acid may give rise to OAG. via the
act ion of phosphatidate phosphohydrolase , leading to increase of activity of PKC
act iv ity and sUbsequent contraction . Basal influx of extracellular Ca-. and an as
yet unidentified tyrosine kinase , are cri tical regu lators of a 2-adrenocept or coup ling
to phospholipase O.
30
Clearty , the smooth muscle at centra l bfood vessels contains both 0,-and
a~ptors. Eachof these receptor subtypes is coupled to a dist inct effector
mechan ism that mediates vasoconstri ction. The spina l admi nistration of eithe r 0,·
or 02-ag onists cou ld be neurot oxic if prolong ed vasoconstriction and thus a
susta ined ische mic state were to arise .
As SU'TUllaIiZed in Table III, a.JITentexperimenta l ev idence suggests that the
spinal administrat ion of individua l a -adrenergic agon ists is without
neurotoxicolog ical effects. Howe ver . the safety of a spina l a , - + a )-agon ist
combination , effecting independent vasoconstricto r mecha nisms, has not been
investiga ted.
Table )
Studiesof Spinal Neurotoxicity Following Intrathecal or Epidural Administration of a-Adrenoceptor Agonists.
Drug! RootelReference Species Dose Tes' Histology Spinal
Neurotoxicity
clonidincJepiduraV sheep daily dose on weekly SEP,HD ught No
Eisenach et al. ( 1984) schedule from0.110 0.6
mglkglday
c10nidincJepidurall sheep total dose 0£2.0 10 2.8 AN, HO, Light No
Eisenachet al. ( 1984) mglkg BO
c10nidincJepiduraU sheep daily dose on weekly SEP.HD Light No
Coombset al. (19841) schedule (rom0.110 0.6
mglkglday
c10nidinelintrathecall dog u .s or 2S Ilglkg once Behaviour ligh t No
Gordhetal. (1984) daily for 14 days Body
Weight
c10nidinelintrathecaV
'"
I ,63 or 16.31lg once Behaviour Light + EM No
Gordh1:1al. (1986b) daily (or 14 days Locomotion
ST-91/ intrathecall ca l 2000 ug oncedailyfor 7 • light No
Yaksh and Reddy (1981) days
ST-9lJintrl theclll monkey 4000ll g AN
Yaksh and Reddy (1981) Behaviour"
Tendon reflexes,l ocomotion, muscle strength, food and water consumption
!:1
Abbreviations: AN, entinociception; BO, blood gases;lID, hemodynamics; SEP, somatosensoryevoked potentials
,."', ,,'" '-VII ' U
Drug! RoutelRefen:nce Species Dose Test Histology Spinal
Neurotoxicity
guanfacine/intrathecal! rat 16.3 or 75 Iig once daily - Light +E M No
Gordh et al. (1986b) for 14days
oxymerezotine/ rat 100 nmol twice daily for AN Light + No
intrathecal!Loomis er al. threedays or 200or 300 Immunehistc-
(1992c) nmol once daily for chemistry
threedays
- -
-
~
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1.7 Combination Drug Therapy
While spinal opio ids and loca l anesthetics can ach ieve clinically effect ive
acute pain control , none do so without attendant adverse effects . Spinal opioids
can produce respiratory depression (immediate or delayed), neurological
abn ormalities (i.e. confusion). urinary retention and pruritis. Spinal local
anesthetics cause postural hypotens ion, bradycardia and urinary retention . Elderly
patients or patients with chronic obstructive pulmonary disease are also at risk of
local anesthetic-induced respiratory depression (Cous ins and Bridenbaugh, 1988) .
To minimize the problem of adverse effects and toxicity, alternate strategies have
evo lved in acute pain management. One example is the concept of balanced spinal
an esthesia. Th is is achie ved by administering low dose comb inat ions of the
ana lgesic drugs , each with separate and potent ially synerg istic mechan isms of
act ion . In appropriate doses, these comb inations produce a level of
anesthesia/analges ia comparable to that of a large dose of a single drug whi le
minim izing their individual adverse effects .
c -Adrenerqtc agonists represent a novel drug class of spinal analgesics.
Used alone , analgesic doses produce pronounced hypotension and bradycardia.
Addit ionally, the variability in the analgesic efficacy of a -agonists in humans makes
the ir independent use unre liabl e. Howe ver, when used in comb ination with local
anesthet ics and op ioids, the spinal administra tion of a -agonists has been
demonstrated to have positive pharmacokinetic and pharmacodynamic effects . For
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example , Lt. clonid ine, at doses wtIich were otherwise inactive , prolonged the
duration of action of tetraca ine in laboratory animals (Sadder at aI., 1986; Mensink
at al., 1987) and ofbupivacaine in humans (Raele at al., 1987; Racle at al., 1988) .
This effect, which was dose-related (Bonnet at al., 1992) , is suggestive of a
pharmacokinetic interaction. In contrast, i.t. clonidine or norepinephrine
significantly reduced the E0 50 of i.t. morphine or DPDPE in mice (Roorig at at ,
1992). Intrathecal metomidine and oxymetazcline produced a simi lar interaction
with i.t. morphine in rats (Sherman at al ., 1988 ; Ossipov at al ., 1990a). In humans,
the combination of epidu ral clonidine and fentanyl produced additive analgesia in
a study of cesarean section (Eisenach at at 1994) . Clinical studies have also
shown a synergism between opioids and a 2-agonists in the treatment of opioid
refractory cancer pain (Pclati et at , 1996) . These resu lts suggest a
pharmacodynamic interadion between a-agonists and opioids , consistent with their
antinociceptive/analgesic activity. Interestingly, clonidine has been shown to
prolong the duration of analges ia of epidural morphine and fentanyl in humans
(Motsch et aI., 1990; Rostaing et aI., 1991) . These data suggest that both
pharmacodynamic and pharmacokinetic factors underly the interaction of a-
agonists with spinal cpioids.
The combination of low dose local anesthestics and opioids in spinal
anesthesia/analgesia has also become popular (Miller, 1994). For example , Cullen
et al. (1985) studied a mixture of morphine (0.01%) and bupivacaine (0.1%) in the
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control of ma;or post-operative pain. In th is double-blind study. pain score s in the
morphine alone and the morphine-bupivaca ine combina tion groups were
signlficantty reduced cxrnpared to tho se of bupivacaine alone . M ixtures of epidural
sufe ntanil (O.1.Q.2IJglml) or fentanyl (1 IJglm l) with 0.125% bupivaca ine are now
commonly used during labour (youngstrom at aI., 1984 ; Vertomman at al ., 199 1).
Interestingly, the adcfrtioo d epineptrine (diluted 1:800.000 to a fina l ooncenuation
of 1.45 IJglml) prolonged the duration of action of a bup ivaca ine-fentanyl
combinati on, thereby reducing the need for supplementary doses to sustai n pa in
contro l (Grice et at, 1990).
1.8 Rat iona le a nd Specific Objec tives
LOW" dose combinations of analgesic and/or anesthet ic drugs are being used
incre asingly to optimize pain control whi le minimizing the prob lem of adverse
effects. a-Agonists such as epinephrine and phenylephrine are routinely used in
combinat ion with spinal loca l anesthetics (Cousins and Bridenbaugh, 1988 ) and
a 2--agonists are be ing used adjlSldively with spinal opioids . Thus , it is ina easingly
likely tha t a-agonists with varying selecti vity tor a 1- and a 2- adrenoceptors will be
adm inistered perisp ina lly (either concurrently or serially) as components of a
multiple drug approach to pain control.
Curren t evidence suggests that 0 1- and q -adrenergic agonists possess
dis crete anlinociceplive mechanisms (see section 1.3). Thus . their co-
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administrat ion in the spinal cord raises several important pharmacological
qu est ions. Does the combination of l.t, 01- and a 2-adrenergic agonis ts effect an
additive CX'"~itive antinociceptive interaction? Can a spinal antinociceptive
combinat ion of Ql- and a~ agonists be used with out risk of ischemic toxici ty given
thei r potent vasoconstrictive effects and the overt neuro toxicity ind uced by Lt,
peptides that cause localized vasocontriction in the spinal cord? Coukt an 0 ,· and
Q2-ago nist combination exacerbate the adverse effect of a known spinal
l'lelXOtoxi'l ? The pc.rposeof this resean::hwasto invest igat e these questions in an
animal species (rat) whose spinal blood supply resemb les that of humans . and with
a known vul nerabi lity to ische mic netxOto xicity . The specific objectives of this
research were :
1) To determine the dose-response relationship of i.t. OX, alone and in
combi nation with a fixed dose of MX (10 1-19), in the tail fl ick and paw
pressure tests.
2) To detennine if a combination of i.t OX and MX, inrectec:l twice a day
for four consecutive days, induces spinal neurotoxicity.
3) To determine the effect of a combination of i.t. OX and MX on Lt.
dynorphi n-indueed neurotoxici ty.
2.0 METHODS AND MATERIALS
2.1 Anima ls
All experiments were conduded using virus antibody free (VAF), male,
Sprague-Dawl ey rats we ighing between 300 to 400 grams at the time of
experimentation (Char1es River Inc. , St Constant, Que., Canada). An imals were
housed in a climate controlled room (22 - C) with a 12 hour (h) Iight-dark cycle
(Itghts on at 07:00 h). Puinalm laboratory rat chow and tap water were provided ad
fibffum. Rats were housed in group cages prior to surgery for a minimum of one
day. All procedures were approv ed by the Animal Care Commi ttee of Melll()(i a l
Un ivers ity in ac:cofdance with the Guide lines of the Canad ian Council on Animal
Care.
The rat was chosen as the experimental model for this thesis as the rat
spina l cord arterial suppfy bears an almost exact resemblance to that of humans
(Scremin, 1995). Given the focus of the thesis and the experimental use of
dexmedetomidine in clinical trials, extrapolation of the results of the
neu rotoxicological evaluation of this drug to the use in humans wou ld be best
achi eved using an animal model tha t closely resembled the human condition.
Additiona lly , in the choice of a positive control for this thes is, it was important to
select both a model and a drug, that had been well documented in the litera ture,
against wh ich to gauge the neurotoxici ty of the drug(s} be ing evaluated . As, the
majority of spinal neurotoxicity studies has been done in the rat, it was chosen as
the model for the experimen tal work.
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2.2 Surgical Procedures
2.2.1 Implantation of Intrathecal Catheters
Rats were implanted with intrathecal catheters using the method of Yak$h
and Rudy (1976) as modified by Sherman at al (1988). Intrathecal catheters were
prepa red from polyethy1ene tubing (PE 10) stretched to approximate ly 1.5X its
origi nal length . A small loop was made approximate ly 4 an from one end of the
cathet er and fixed with adhesive . The section of the catheter betcw the loop was
trirrrned to a length of 7.5 em. Immediately prior to implantation. the cathete r was
flushed with ster ile (0.9%) saline (Astra Pharma Inc.).
Anaesthesia was inducecl with 4% halothane (Halocarbon Laboratories,
River Edge, N.J.) in oxygen (100%) and the rat was placed in a stereotaxic
apparatus (Narishige Type SN-2, TOkyo, Japan). Anaesthesi a was maintained with
2.0-2.5% halothane . A transverse cut was made at the base of the head and the
atlanto-occi pital membrane was exposed. The catheter was inserted through a
small slit in the cisternal membrane , and guided carefully ttv ougtl the spina l
subarachno id space so that the tip was posit ioned near the lumbar enlarge ment
The catheter loop was sutured to the overlying IT'KJscle and the rostra l end of the
cathe ter was then passed under the skin and externa lized on the top of the skull.
The catheter was flushed with 10 IJI of sterile saline to clear the cathet er of any
blood or debris, and sealed with a stain less stee l plug. The inci sion was then
closed with sutures and halothane was discontinued .
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Anima ls were housed individually after surg ery and all owed to recover for at
least four days before experimentation . The t.L catheter were flushed the next day
with sterile saline and the surgical incision was deansed with 10% hydrogen
peroxide (H"Oozl and trea led with an anti-infla mmatory crea m (Viaderm K C. Cream
(Tewo». Only anima ls with norma l posture and gai t, and exhibiting normal eating,
drin king and grooming behaviour were used for experiments.
2.2.2 Implantation of Intravenous Catheters
Jugular vein catheters -.wre made from twosizes of $ilasticf) tubing. 0.020"
X 0.037" X 0.0085" and O.04IT' X 0.085" X 0.0225", Two 7 millimeter (mm)
segnents of the larger tubing were a.rtand ead'l was threaded with a 3 cent imeter
(em) length of nonabsorbable surgical suture (8- 186 Ethicon, Peterborough,
Ontario, Canada). A 12-an length otthe smaller tubing was then threaded through
the two larger tub ing segments. The first segment was positioned 4-an from the
end of the smaller tubing . An imals were ana esthet ized with sodi um pentoba rbita l
(50mg/k g i.p.) and the left jugu lar vein was exposed . The proximal end of the
smaller tubing was inserted into the jugular vein in the direction of the heart . The
position of the catheter, in the vein, was then secu red by tying the sutures of the
over1yingtubing segnent to the surrounding musculature. As the tubing exited the
jugular, a ha lf.loop was fo rmed so that the catheter coul d be passed
subcutaneously to the back of the neck and externalized on the back of the skull .
The loop was secured by positioning and tying the second overlying tubing seg ment
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to the nearby mu scu lature . The externa l ized portion of the catheter was trimmed
to a final length of 3-an and sealed with a stainless steel plug. Animals were
a110Ned to recover for 48 h prior to the experiment and patency of the catheter was
maintained by twice daily injed ions of 50 IJIof sterile saline containing heparin (100
1.Ulml).
2.3 AntJnociceptive Testing
Atltinociceptio wasassessed using the ta il flick (TF) and paw preSSt68 (PP)
tests . For both of the se tests, rats were lightly restrained by hand using a cloth to
co ver the he ad . Th is minimiZed exploratory behaviour and visual stimuli duri ng
testing. Rats were acclimatized to the TF and PP ecpere u the day befor e
expe rimentation beg an. The mean of three con secuti ve measurements in the TF
and PP tests was determ ined at each time point
In the TF test {D'Amour and Smith , 1941 ), the ventral porti on of the tail was
placed over the t-en open ing of the tail flick ana lgesia meter (Muromad'li Kikai
Compa ny, Ltd . Tokyo , Japan). Rad iant light from an evSOW fight bulb . focussed
us ing a reflect or throug h the opening, was used as the heat source . The time
between the onset of the heat source and refle x withdrawal of the tai l (termed the
"response latency" ) was automatically recorded. The light intensity was adjusted to
y ie ld control responses of 3-5 seconds (sec ). In the absence of a response, the
noxiou s stimu lus was termina ted after 10 sec and the cutoff latency recorded.
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Paw pressure threshold (PP) was measured using a Ugo Basile Analgesy
Meter (Ugo Basile. Italy) according to the method of Randa ll and Selitto (1957) .
The non-inf\amed hind paw was placed on a Teflon plinth having a very low friction
coefficient A cone-s haped plunger was placed direct ly above the dorsa l surface
fA the rat's paw. The force exerted on the paw was gradually naeased' at a fixed
rate until a complete withdrawal or withdrawal attempt was made. The force
eliciting a reflex withdrawal was then recorded. A artoff pressure of 1250 grams
was used in all experiments to prevent rnju'y and infl ammation .
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2... Motor Function Testing
To assess motor function and coordination, animals were tested using an
accel erating rotarod (RR) treadmill for rats (Ugo Basile, italy ) aa:ord lng to the
method of Jones and Roberts (1968). The apparatus cons ists of four 7-em
diameter drums , mach ined to provide suitable grip for the rats . The drum was
di v ided by five flanges enabling fOU'rats to be tes ted simultaneously. The drun
acce lerated from 4 to 40 r.p.m. in a period of 5 minutes (min ). The duration on the
rota-rod (in sec) was automati cally recorded for each an imal . Animals were tra ined
on the apparatus for one day prior to experimentation (one train ing trial in the
moming and one in the afternoon). Animals were consid ered trained when they
cou ld remain on the rota -rod for a minimum of 60 sec on t'NOconsecutive trai ning
trial s; a a.rtoff of 300 sec was used . Rota-rod performa nce was calcutetec as the
mean of two consecut ive rota-rod measur ements.
2.5 Immunohistochemistry
At the end of the experimental period , rats were anaesthetized with
pentobarbita l (100 mg/Kg , injected intra--hepatica lly) and perfused transcarclially
with 50 mL of ice-cold hepa rin ized saline (5 I.U. he pa rinl mL) foll owed by 200 mL
of 4% paraformaldehyde at 120 mm Hg. The spinal cord was excised and
ex amin ed for signs of inflammation and haernorrt\age, and the position of the i.t
cathet er was determined . An ima ls were excluded if the tip of the catheter was not
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found in the subarachnoid space nea r the l1 seg ment.
Spinal cores were post-fixed in the same fixative soIutoo at 4 ·C for 16 to 24
h. The segment of the CClf"d adjacent to the tip of the catheter (L1) was taken tor
immu no histochemica l staining . Forty -pm thick tran sverse secti ons of the spina l
cord were processed for substance P (SP }- or calcitonin gene related peptide
(CGRP~ike immunoreactivity (IR), us ing the peroxidase-antiperoxidase (PAP)
method (Sternberger. 1979).
Sect ions were sequentially il'lO.Jba ted in: 1) 10% normal goat serum
conta ining 0.3% H, 0 2 and 0.4% Triton X-1OO; 2) either rabbit ant iserum to SP
(1:2000 dilution; lnestar Corp .) or CGR P (1:10.000 d ilution: Amersham): 3) 1:150
dilution of goat-anti-rabbit-lgG serum (BoeM nger Mannhe im Biochemicals): 4)
1:300 dilut ion of rabbit PAP (Sternberger Meyer Immunochem icals); and 5) 3',3'
diaonino-benzidine HCL (0.5 mglmL ). glucose oxidase (3.8 Ulml, Aspergillus nige r
type V; Sigma Chemicals) and D-gluco se (2 mglmL) in 0.1 M ph osphat e buffer (pH
7.2). Between incubations , sections were washed three times each for 15 min in
phosphate buffered sal ine. Sect ions were then mounted on gelat in-coat ed slides .
Representalive photomicrographs of each treatment group are presented in
the thes is.
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2.6 Drugs and Drug Admin is tra tio n
2.6.1 Drugs
The following drugs were generous ly provided by their manufacturers:
dexmedetom idine HCL (Ori on Corp . Fannos, Turtw , Finland ); methoxam ine HCl
(BlDTOUQhs Well come Ltd., Kirkl and , P.O., Canada); prazosin HCl (PfIZer Canada
Inc., Kir1d<m, P.O., Canada); and Wyeth 27127 HCL (Wyeth Ud .. Philadelpll ia. PA.
USA) . Porcine dynorphin A (1. 13) was obta ined from Peninsula laboratories Inc.
(Belmont, Cal~ia, USA). Dexmedetom idine (OX; (4XS)-{2,3-<limethylpll enyl)
ethyl]-imadazore ) was selected as the Qz-agonist as it is a highly potent and
seledive Qz-agon ist (02 to 0 , rati o of 1620: 1 versus 200 :1 for c1oni dine; Virtanen
at aI., 1988) . Metho xamine (M)(; 2-am ino-1 -{2.5-d imethoxyphenyl) propan-t-ot
hyd rochloride ) was chosen as the 0l-agonist beca use it produces fewer motor
effec ts tha n the other a 1-agonists avai lable and because it has a slightl y greater
a,taz selectivity ratio in displaci ng ['H] praz osin and [~lp-aminoclonidine from
binding studies in rat spinal cord membra nes (Simmons and Jone s, 1988 ). Wyeth
27 127, a disutphona midQ..benzoqu ino lizine compound wt'lich is equ ipoten t wi th
idazoxa n in bfod<ing aradr'enoceptors in isolated smooth mu scle preparation, was
used because its a t :a 1 selectivity ratio is cons iderab ly greater tha n idazoxan (Bill
et at, 1986). praz osin is a classica l a i-selective antagonist wt'lich has bee n used
ext ensively to charact erize adrenergic binding sites and functional e -
adrenocep tors . The neurotoxin used in th is study was dynorphin A (1-13), a
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naturally ocO,ming thirteen amino acid peptide known to produce behavioral and
histological neLrotoxicily following i.t injection in the rat (Faden and Jacobs , 1984 ;
HetTna-1and Goldston. 1985 ; Sparr,linato and Candeletti, 1985; Long et al., ' 988;
Stewart and Isaac. 1989) . All drugs weredissolved in steri le saline (Astra Pharma)
except prazosin 'Wtlich was dissolved in dimethyl sulfoxide (OMSO). All drugs were
prepared on the day of the experiment Doses are expressed as the salt.
2.6.2 Drug Adm in istration
All the l.t, drugs , except the pre-treatment irlections in the dose response
experiments and dynorp hin. were injected through the i.t. cathet er in a volume of
10 IJl folJowed by 10 I.ILof saline using a hand-he ld 101Jl Hamilton syring e. For
the i.t. pretreatment experi ments, the adrenergic antagonists were injected in a
volume of 5.0 IJL followed by a 10 I.ILsaline flush using a 10 IJL Hamilton syringe .
Dynorphin was injed:ed in a volume of 5 I.IL. using a hand-held SiJ L dead vo lume
Hamilton syringe , followed by a 10 !JL saline flush. lnjedates were gradually
infused over 30 sec to min imize the increase in CSF pressu re . Intravenous drug
inject ions weregiven in a volume of 0.1 mL followed by a O.1-mL saline flush . For
all drug inject ions . rats were placed in a d oth restra iner (Owen et at. 1984) to
whidl they had been previo usly acclimatiz ed.
2.7 Experimental Protocols
2.7.1 Dose-Response Experiments
The effect of i.t administration of dexmedetomidine (DX), in doses ranging
from 10 ng to 1 1J9,on tail flick latency and paw pressure threshold was examined .
Tail flick latency and paw pressure thresho ld were dete rmined immediately prior
to and 15. 30 , 60 and 90 min following the i.t ir1ection.
The dose response experimentwas repeated using a fixed dose of 10 ...9 of
methoxa mine (MX) with the various doses of Lt. Ox. Tail flick latency and paw
pressure threshold were again determined at the same time points as the in itial
experiment
To characterize the pharmacological interad ion between i.t. OX and MX, Q-
adrenergic antagonists were given 10 min before a fixed dose combination of 0.025
1-19 OX + 10 ...9 MX. Th is dose combination was selected for the antagonis m
experiments because it yielded a near maximal effect (88% :t 19.2% maximum
possible effect (MPE): mean 1: SO; n=19) in the tail fl ick test. and an intermediate
effed. (41.go,k 1: 30.5% MPE: mean t SD: n=19) in the paw pressure test Tail flick
latency and paw pressure threshold were detenn ined immediately prior to the
injection of the Q-antagonist and 15, 30, 60 and 90 min following the injection of the
OXlM X combination .
2.7.2 Single and Repeated Intrathecal Dosing wi th OX and OX + MX
As part of the neurotoxicological assessment , tai l flick latency aOO rota-rod
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performance......ere detennined after eaen d eight conseaJtive l.t, injections. For the
PLWPOse of neurotoxicological assessment. maxima l drug doses over and above
that of phannacological indices would have to be adminis tered . The doses chosen
were 10 1J9OX and 10 ~ OX + 10 ~ MX whidl represent a 100 and 25 fold
increase over the TF and PP ED:so's . respectively. The inject ions were done twice
a day (one in the mcming and one in the afternoon) for four consecutive days . The
treatments were inject ed in a 10 IJL vo lume fol1O'Ned by a 10 IJL sal ine flush. The
Lt. injections were graduall y infused over 30 sec to minimize the increase in CSF
pres5lS8. Ta il fficklatency wasdetermined inmediate ly prior to and 15 and 60 min
after the inject ions. Rota-rod performance wasdetelTT1ined immediately prior to and
15. 30 , 60 and 90 min after the i.t i~ons.
2.7.3 Acut e Intrav enous Study
The effectof i.t doses given by i.v. injection wasalso determined in rats fitted
with il1d'vv'elhng jugu lar vein cathete rs . The treatme nt groups were sa line , 0 .025 1J9
OX + 10 IJ9MX, O.251JQ OX + 10 IJ9MXand 10 IJO OX + 10 1JQ MX. The treatments
were inject ed in a 0 .1 mL volLMT19 followed by a 0.1 mL saline flush. Both tail fliCk
latency and rota-rod performance weredetennined immed iate ly prior to and 15 and
60 min after the i.v. inject ions.
2.7.4 Pre-treatmen t Study
The effect of pre-treatment of rats with i.l OX, MX.or OX + MX before an i.t,
injection otdynorphinA, a knovvnneurotox in , was exami ned . Sal ine, 10 1-19 OX, 10
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IJQMX. or 10 IJQ OX + 10 ~ MX.were intratheca lly injected 15 min before an Lt,
injection of dynorphin A (1-13). Initial doseresponse experiments using 60, 80, 120
and 150 nmol of i.L dynofphin. were done to establ ish a neurotoxic dose for this
study . A dose of 60 rmoI (96 ~) produced transient hindlimb paralys is, reversible
loss of the tail flick.reflex and no histological evidence of spinal neuro toxicity. At
120 rmoI (193 lJ9l. dynorpt'lin consistertly produced irreversible hindlimb para lysis
and loss of the stepping and tailflick ref\exes (data not shown). The pre- treatments
were injed ed in a 10 IJL volume followed by a 10 IJL saline flush while dynorphin
A was injected in a 5 IJL volume followed by a 10 IJL saline flush.
Tail flick latencies were detenni ned immediately prior to the pre-tre atment ,
15 min after the pre.trea trnent (and immediately prior to the dynorphin injection ), 5
min and 24 h after the dynorphin injection . Rota-rod performance was determined
immediately prior to the pre-treatme nt injections and 24 h after the dynorp hin
injection.
Motor functi on was assessed using the rotarod and stepp ing reflex tests.
Tes ting was done immed iate ly prior to the injectio ns and 24 h followi ng the
injecti on.
2.7.5 Hypothennia Study
The effect of l.t, administration of OX and OX + MX en body temperature was
exam ined . 10 IJ9 OX . 10 lJ9 MX or 10 IJ9 OX + 10 IJQMX was injected Lt. The
treatments were injected in a 10 IJL volume followed by a 10 1JLsaline flush.
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Rectal temperature was recorded using a Harvard Homothermic Blanket Control
Un it rectal tempera ture pro be . Temperature was record ed immediately prior to
in;ectionand 15, 30 . 60. 90 .120. 150.160, 210 and 240 min.
2.7.6 Neuroto xicity Study
As part of the neurotoxico logical assessment, the spinal cords of rats in both
the sub-dvonic intra thecal and the pre-treatment studies were excised and
immunOhistochemical stain ing for substance P (SP) and ca lcitonin gene related
peptide (CGRP) done. From the sub-chronic i.t behavioural study , processing of
the rats , for staining, began 12 h after the last injection of sal ine . OX and OX ...MX
and 48 h after the injection of dynorphin. From the pre-treatment behavioural study,
processing of ill!animals began 48 h after the irledion of dynorphin. (See Section
2.5 for Il'TU'TUlOhistOChemistry details ).
2.8 Data Analys is
Both the tail flick and paw pressu-e results were expressed as percent of %
MPE which was calculated as
' MPE a pos t drug r esponse - pre drug control
c u t o f f t ime - p re drug con t rol
x 100
Rotarod results were also pkJtted using the 15 time point value s and are expressed
as percen t of the base line (% baseline) which was calculated as
so
% bas eline "" post drug respon se X 100
pre dr ug r e spo nse
TIle mean and standard deviat ion s of the TF . PP and RR results were calcu lated ,
Dose response curves were constructed from the time course data using the
maxirrun response obtained in the tall flickand paw pressure tests which occurred
at the 15 min time poi nt. EOsovalues and 95% confi dence intervals for the dose
response 0JVeS were calcu lated using the method of Tallarida and Murray (1986) .
For the gaphs for the repeated i.t. doses and the i.v. studies. means and standard
deviat ions of the MPE's and % baseli ne's at the 15 min time poi nt were used .
For the dose response and pre-treatment stud ies , statistica l analysis across
the treatment gro..ps was conducted using one-way analysis of variance (ANOVA)
followed by Newman-Keuls test for a significa nt F--ratio (p<O.05) . For comparisons
between twotreatment groups, the student 's t-test was used .
For the repeated i.t dos ing study, statisti ca l differences were determined
using the Mann-Whitney two sample test
For the Lv. study. between group repeated meas ures ANOVA followed by
NeYomarl-Keuls and within group repeated rneasl.I'eS ANO VA followed by Newman--
Keuls were used to determine sta tistical signifICance .
3.0 RESULTS
3.1 Dose-Response Relationships of DX and MX in the Tail Flick and Paw
Pressure Tests
Intrathecal OX (10 ng - 1 IJQ)signific:antIy inaeased tail flick latency and paw
pressure ttreshold. The time of peak antinociceptive activity ranged from 15 to 30
min after ir1edim. depencfJngon the dose (data not shown). The dlration of action
for a nea r maximal dose (0.15 1lQ) was 90 min. As shown in Figure 3, the
antinocicep tive effect of Lt. OX was doSEKSependenl The E0 5ll 's and 95%
confidence intervals of i.t. OX in the tail flick and paw pressure tests are
summarized in Table lV.
TABLE rv EOso'. and 95% Confidence Intervals (ng) of Intrathecal
Oexmedetomidine Alone and In Combination with Intrathecal
Methoxamine.
TREATMENT
Oexmecletom idine
Oexmedetomidine +
Methoxamine
TA IL FLICK TEST
44.5 (17.9 - 110)
8.12(6.56-10.1)
PAW PRESSURE TEST
252 (149 · 425)
10 (9.0 - 11.6)
The co-administrationofa fIXeddose ofi .t. MX (10 ~ i.t.) with OX produced
a significa nt leftward shift in the OX cIose-response curve (Figure 3), and a
corresponding 5.S-fold inaease in the po tency of OX in the ta il flick test , and a 25-
fold increase in the paw pressl.I"e test (see Table rv). Methoxamine (10 IJQ Lt ) itself
yielded less than a 5% increase in the maxilTlU'Tl percent effect (MPE) in the tail flick
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les t, and no change (0% MPE) in the paw pressure test (data not shown). Mild
hypereflexia and oo::asionat serpentine tail movements were observed irTmediately
after i.t. MX but these gen erally lasted less than 5 min .
Intrathecal prazosin (2.5 or 10 ~) signfficantly attenuated the
antinociceptive effect of the OX + MX combination compared to dime thyl sulfoxide
(DMSO)-pretreated rats (Figure 4). Indeed , complete blOCkade was observed with
the higher dose of prazosin in the paw presswe test Intrathecal DMSO. the
injection vech icle for praz osin. had no effect on the interaction wh en compared to
naive or saline-pretreated rats . The 0 a-antagonist, Wy 27 127 (0.5 IJ9 i.l)
completely blocked the antinociceptive effect of i.t. OX + MX in both tests. The
res idua l effect observed after prazo sin (10 pg) blockade in the ta il tlick test was
equivalent to that of 0.025 IJgOX alone (see figure 3) . Th ese data are consis tent
with the predominate role of a 2-adrenoceptors in the adrenergic modulation of
spinal nociceptive transmission, and the invovlement of spinal a, -receptors in the
dexmedetomidine + methoxamine interaction.
3.2 Effect of Single and Repeated Dos ing of OX + MX on Rota-Rod
Performance and Tail Rick Latency
The Lt. injection of OX (10 \-Ig) completely inhibited ro ta-rod performance in
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PAW PRESSUAI
Figure 3 Log dose-response curves of intrathecal dexmedetomidine atone ("l.
and in combination with a fIXed dose of intrathecal methoxamine (10 ~; . ) in the
tail flick and pa.v pressure te sts. Data are expressed as the mean 1: S.D. of 5 - 10
rats. EDso's and 95% CXll"Ifidence intervals are sumarized in Table N . Methoxamine
itse lf yielded < 5% MPE in the tail flick test, and no change (0%) in the paw
pressure test (data not shown) .
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TAIL FLICK
PZU 1'Z1' .., ...
OX.III: • • _ IIX• •
PAWPRESSURE
100
Figu re 4 The effectofi.t prazosin (PZ; 2.5 and 10 ~g), Wyeth 27127 (WY; 0.5~)
or OMSO (vehicle ) injected 10 min befo re i.t. dexmed eto midine (OX; O.0251JQ) +
methoxa mine (M)(; 10 ~). Data are expressed as the percent of maximum poss ible
effect (%MPE) determ ined 30 min after a.agonist injecti on and rep resent the mean
:t SEM 0(5 -19 rats . AUpretreatrTlerUwere significantly different from V'" OX ...MX
as determined using one-way AAOVA and NelAan-Keuls (p < 0.05).
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this study (Figu re 5), and produced a max imal increase in ta il flick latency (Figure
6) . Rats weredearly sedated (ab sence d a righting reflex. no start le reflex) at this
dose with reco very oco.ning 120 min after injection. There was no evidence of
pennanent motor dysfunction or other adverse eff ects as the drug treatmen t effeds
were completely reversible. 8egiming at approximately 120 min post tn;edion , the
an imals regained the righting and startle reflexes, normal body posture and
rest.med grooming, feeding and drinking and exp loratory beha viour. These effects
we re unchanged by the add ition of MX (10 IJ9 i.t) (FtgUres 7 and B).
Repeated dosing with OX an d with OX + MX produced the same effects as
the initial injecti ons . Rotarod performance was completely inhibited (see Figure's
5 and7) anda maximal incr ease in tail flick latency was produced (see Figure 's 6
and 8). The effects were comp letely reversible afte r each dose of either OX or OX
+ MX. While the an imals exhibited the same magnitude of effects in the RR and
TF tests between the first and the eighth injections. the duratio n of the effects
decreased sugg esting some degree of to lerance (refer to the upper two graphs in
Figur es 5 to 8).
There wasno evidence c:A c:uroolative toxicity as the appearance, behaviour
and overall adivi ty of the anima ls was the same in the sa line an ima ls and those
anima ls that had received both OX a nd OX + MX, even afte r a full course of eight
injed. ions . An ima ls looked hea lthy and exhib ited norma l grooming , feeding and
drinking an d locomo tor behav iou rs.
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In sunmary, each i.t injection d 10 \J9OX and 10 IJQ OX. 10 5Jg MX elicited
the e:wpectedpharmacological effects as assessed using sensory and mo tor tests .
Although , this testing might seem unnecessary given that the dOses chosen
represent a 100 told (tail flick) and 25 fold (paw pres sure) incr ease over the EDso's
(see Table lV), it was necessary to ascertaJn that ead'l l.t, iflection was exerting a
pharmacological effect. The animal s exhibited the same magnitude of effects in the
RR and TF tests between the first and eighth injections for bo th the OX and OX +
MX treated goups. TIlere appea-ed to be sane small measure of tolerance as the
recovery from the injections was faste r after the eigh th injecti on as compared to the
first irfection. ., the assessment of the animals' behaviour. the repealed dosing did
not appear to resun in any cunulative toxicological effect s as the anima ls appe ared
healthy and exhibited normal grooming, eating and drinking and exploratory
behaviour.
•o
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Figure 5 The eff ect of I.t dexmedetomidine on rota-rocl perfonnanc8. Lower
flQlX8: The effectof tt, dexmedetomidine (10 ~) or saline on rota-rod pe rformance
determined 15 min after each of eight consea.ltive injecti ons (two injections per day
for 4 da ys ; one in the morning and one in the aftern oon). Data are expr essed as
the percent of baseline performance (e.g. rota-roo perfonnance before each
injectio n). The solid triangles represent the mean :f: S.D. of 5 rats; the open and
solid circles represent individual saline-treated controls. All lime points for the
dexmedetomidine treated animals were significantly different (p < 0.05) from the
sa line treated animals (Mann·Whitney Two Sample test). Upper fig ure: Thetime
course of rota-rod performance after the first and last injection of i.t.
de xmede tomidine (10 1J9).
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Figure 6 The effect of f.t dexmedetom ldine on tail flick latency . lower figure:
The effect of i.t, dexmedetomidine (10 JJ9)or saline on tail flick latency determined
15 min after each of eight consecutive injections (two injections per day; one
injection in the morning and one in the afternoon). Data are expressed as the
maximum percent effect (% MPE). The solid triang les represent the mean t: S.D.
of 4 rats ; the open and solid circles represent ind ividual saline -treated controls. Al l
time points for the dexmedetomidine treated animals were significantly different (p
< 0 .05 ) from the saline treated animals (Mann-\Nhitney Two Samp le tes t). Upper
figure: The time course of tail flick latency after the first and last injection of It,
dexmedetomidine (10 ~). Data are expressed as the mean of the raw tail flick
scores with the cutoff time being 10 sec.
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Figure 7 The effec t of I.t dexmedetomldlne and methoxamine on rota-rod
performance. Lower figure: The effect of Lt. dexmedetomidine (10 IJQ) +
metho xam ine (10 1J9)or saline on rota-rod performance detenn ined 15 min after
each of eight consecut ive injection s (two injections per day for 4 days; one in the
rooming and one n the afternoon). Data are expressed as the percent of base line
performance (e.g. raa-rod performance before each injec::tial). The solid triangles
represent the mean::l:S.D. d 8 rats ; the open and sol id circles represent individual
saline-trealed controls. All time points for the dexmedetomidine and met hoxamine
treat ed animals were significantly different (p < 0.05) from the saline treated
animals (Mann-Whitne y Two Sample test) . Upper figu re: The time course of rota .
rod performance after the fIrStand last injection of l.t, dexmedetomidine (10 1J9)+
methoxami ne (1a 1J9).
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Fi gure 8 The effect of i.t dexm edetomidine and methoxamine on tail flick
latency. Lower figure: The effect of i.t. dexmedetomidine (10 ~g) + metho xamine
(1 0 ~g ) or saline on tail flick latency determined 15 min after each of eight
consecutive injections (two injections per day; one injection in the morning and one
in the afternoon). Data are expressed as the maximum percent effect (% MPE).
The solid triangle s represent the mean ± S.D. of 4 rats; the open and sol id circle s
represe nt individual saline-treated controls. All time points for the
dexmedetomidine and methoxamine treated animals were significantly different (p
< 0 .05) from the saline treated animals (Mann-Wh itney Two Sample test). Upper
figure: The time course of tail flick latency after the first and last inject ion of i.t.
dexmedetomidine (10~) + methoxamine (10 1J9). Data are expressed as the mean
of the raw tail flick scores with the cutoff time being 10 sec.
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3.3 Effect of t v. Dexmedetomidine + Methoxamine on Tail R ick Latency
and Rota·Rod Perfonnance
To assess the poss ibility of peripheral antinociceptive and motor effects of
the OX + MX combination , i.t doses (0.025 IJQ OX + 10 jJQ MX, 0.25 1.19 OX + 10 JJQ
MX , 10 1-19 OX + 10 IJQ MX) were injected Lv. and tail flick latency (Figure 9) and
rota-rod performance (FigLn 10) detennined. LOINdoses of OX (0.025-0.25 1J9) in
combination with MX (10 1J9) had no effect on tail flick latency or rota-rod
perform ance. In contrast, high dose OX (10 1J9) in combmation with MX (10 1J9)
almost completely inhibited rota-rod perfonnance (Figure 10J and significantly
increased tail flick latency (Figure 9).
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10Jl9 MX
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0.25/19 OX
+
10J/g MX
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+
10 JIg MX
Agure 9 The effect of t v. saline or dexmedetomldine + methoxamine on tall
n ick latency. Doses of 0.025 IJQOX + 10 IJ9MX, 0.25~ OX + 10 IJ9MX.10 IJ9
OX + 10 IJ9MX Of saline was i'1ectedintravenously and tail ftieXlatency determined
15 and 60 min after injection Data are expressed as a percent of the maximum
possible effect with each bar representing the mean:t:S.D. rA5 - 10 rats . Statistics :
(1) Between groups repeated measu re s AJtlOVA followed by Neuman-Keul s. The
15 and 60 min readings of the 101J9OX + 10 IJQ MX dose are sign ificantly d ifferen t
from the three other groups (ANOVA:p<O.OOO1 ; Neuman..Keuls:99% confidence) .
(2) Within group repeated measlI'8S ANQVA followed by Neuman-Keuls. Only the
10 IJO OX + 10 IJ9 MX's 15 and 60 min values are different from the base line
(ANOVA: p<O.OOOl; NeumarH<eu ls:99% confodence).
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Figure 10 The effect of I.v. saline or dexrnedetomidine + methoxamine on
rota...-odperformance. Doses of O.025 1JO OX + 10 IJO MX.,0.25 jJg OX + 10 J.IQ
MX, 10 IJg ox + ' 0 1-19 MX or saline was injected intravenously and rete-roc
performance determ ined 15 and 60 min after injection . Data are expressed as a
perce nt of the basel ine performance (e.g. rotrrod performance before injection)
with each bar representi ng the mean :t S.D. of 5 • 10 rats . Statistics: (1) Between
gl'OLp5 repeated meaSl.reS~OVA follo,¥edby Neuman-Keuls. The 15 and 60 min
readings of the 10 IJ9 OX + 101J9MXdose are significa ntly differen t from the three
other grt)l.4:ls (ANOVAp<O.0CJ01 ; Neunan-Keu1s:99% c:onfidence ). (2) Within group
repea ted meaSlS8SANOVA toI1owed by Neunal-KeuIs <a) 0.251JQ OX + 10 IJO MX;
The 60 min reading is signifICantly different from the baseline read ing (ANOVA: p
<: 0.05; Neuman-Keuls ; 99%). (b) 10 ~ OX + 10 IJg MX: the 15 and 60 min
readings are significantly different from the base line (ANOVA p<O.OOO1 ; Neuman-
Keuls : 99% confidence) .
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3.. Evaluation of Spinal Cords FoRowfng Repeated l T. Dexmedetomidine
and Methoxamine Administration.
Inspection of the spinal cords from rats treated with i.L saline,
de)(J1l8(jetomjdine (10 IJQ') ordem'ledetomidine ( 1 0 ~) + methoxamine (10 IJO)twice
dai ly for four days revealed no evtdence of inflammation, haemrnontIage or
necros is near l 1 (adjacent to the tip of the Lt.catheter). There was no detectab le
change in the sta ining pattern or intensi ty of substance P-immunore ad ive (SP-IR)
structures in the dorsal hom of dexmedetomidine or dexmedetom idine +
metho xam ine trea ted rats as compare d to saline controls and no loss or damage
to calcitonin gene related peptide-irmulor (CGRP-IR) motor net.rorlS in the
ventra l hom (Figur e 11). However , 48 h after a single l.t, injection of dynorph in A
(1-13) (120 MlO I) there was extens ive damage to and loss of CGRP·IR neurons .
The motor neurons remaining in the ventral hom were abnorma lly shaped, small in
siZe and weakly staining for CGRP. SP-IR staining of fibers in laminae I and II of
the dynorphin treated rats was unc:ha nged from that of the sal ine-treated rats
indicating a neurotox icity that was selective for the motor neurons in the ventral
ho m only . Hindlimb paralys is and irrevers ible loss of the tail nick refle x were
observed almost immediately after the dynorphin injecti on in these animals.
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Rgure 11 Photomiaograph s of substance P-irrmunoreact.i vity in the dorsal hom
(left celunn) and calcitonin gene related peptide (CGRP)-immoooreactivity in motor
nelXOnS (right column ) of spinal cord sections (L1 segment) from animats treated
with : A and B) intrathecal (i.t ) saline twice daily tor four days; Cand O) i.t
dexmedetomidine (10 ~) twice da ily for fot.r days ; E and F) i.t dexmedetomidine
(10~) + i.t methoxamine (10 1J9) twice dai ly for four days and G and H) a single
inject ion of dynorphin A (1-13) (120 nmol , 193 1Jg). Magnification bar is 200 pm,
There was extensive damage to and loss of CGRP -IR motor neurons in the ventra l
hom d Lt,dynotphin - treated rats . There was nodetectable change in the staining
pattern in SP-IR structures in the dorsal hom of e ither the a-agonist or dynorph in
treated rats as compared to the saline controls.
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3.5 Effect of OX or OX + MX on i.l Dynorphin-lnduced Neurotoxicity.
Initial dose-response experiments using 60.80. 100. 120 and 150 nmol of
i.t, dynorphin showed that a 60 nmol (96 ~) dose produced no evtdence d
behav ioural or immunohistochemica l evidence of neurotoxicity. At 120 rvnol (193
1-19). dynorphin produced irreversi ble hindlimb para lysis. loss of the stepping and
tail-flic:kreflexes and loss of CGRP-IR net.Xons in the spinal cord (see Section 3.4) .
The 150 " mol dose was lethal . In testi ng the effect of pre-treabnanl with Lt, a -
agonists on dynorphin toxicity , we observed evidence of neuroprotection aga inst
the 120 nmol dose . Thus all saline pre-tre ated rats injected with dynorphin (120
nm o l) exhibited irreversible hind limb para lysis , making them incapa ble of
performin g the rotarod test 24 h after injedion (Figure 12). There was a
correspond ing loss of the stepping refle x (Figure 12) and the TF reflex (data not
Shown) that preceded the development of bladder and bowel dysfunction. In
contra st, pre-t reatment with u , OX, MX or OX + MX (10 1-19 each) attenuated the
hind limb paralytic effect of i.t dynorphin. These doses were selected from the
prev ious sing le and repea ted i.t dos ing study.
As shown in Figure 12, the 24 h rotarod scores for a ll three a..agonist pre-
treated groups were only marginally belCMl' theW" baseline values (or those of sal ine-
treated rats thai did not rece ive dynorphin), and signifi cantly diff erent from the
sal ine-dynorph in group. All four rats recei ving the OX + MX comb ination, three of
five rats rece iving OX, and three of four rats rece iving MX had a norm al stepping
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reflex, 24 h after dynorphin (Figure 12). A similar trend was obs erved with the TF
reflex (da ta not shown). In rats pre-treated with i.t, Ox. the rectal temperatlse
decreased by 3.3 t 0.4DC below base line 5 min after injection and remained below
base[inefa"~to 4 h. In rats pre-treated with Lt, OX + MX. the rectal temperature
decreased by 3.4 :t 0 .3 · C. Methoxamine did not deaease rectal tempera ture.
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Figure 12 The etfectof intrathecal dynorpninA(1 -13) (OYN; 1931JQ; 120 nmor) on
rota-rod performance and the stepping reflex in rats pretreated with : l.t, sali ne
(SAL); de><Jl1edetomidine (OX; 10 I'll) + methoxamine (M)(; 10 I'll); OX alone (10 I'll )
or MX alone (10 IJQ). Rota-rod performance was detenn ined immed iately before
(open symbols; O) and 24 h (d osed~s; 24) after dynorphin administration.
Separate syrrboI s are used for each treatmen t group and each symbol receeseots
an individual animal score. There were no differences in baseline rota-fOd SCX)f"8S
among the four treatment groups (ANOVA; p =0.68). All pretr eatmen ts were
injected 15 min before dynorphin. The + symbol over the 24 h data represents the
mean rota-rod performance in a separate group of rats that received only the pre-
treatment (no dynorphi n). The numbers above the treatment groups at the top of
the figure represent the ratio of animals exhibit ing a l"lOmlal stepp ing reflex after
ctug administration. The mean basel ine and 24 h rota-roc:l scores are indicated by
the - symbo!.
Tab le V
[ ffttt orpre-Irutmenl with inlrath ec:al •• line. des.mtde lomldine and melhoumine, alone and In comblnaUon,
on d)'norphin Iruled rals.
,
Saline! IOX+MX! IOX! (n - 5) MX! (n - 4)
Dynorphin Dynorphin Dynorphin Dynorphin
Non- Non-
Protected Protected Protected Protected
n - 3) (n -2) (n - 4) (n ' 3) (n=2) (n -3) (n e l}
Mean TF 5,4± 2.9 ± 0.42 100 ± 0 100 ± 0 100 ± 0 18.9>23.\ 46.3
latency at 15 5.0
min (MPE) I Cl
Mean TF 2.1 :I: 100 ± 0 94.82:10.3 100 ± 0 ioo s o 48,3 ± 25.1 \00
Latency at 20 2.3
min (MPE)
MeanT F -2.S ± I 100:*:0 1 14.4 :*: 18.41 2.9:*:2.5 1100 :*: 0 1 11,3 ± 13.1 1 \ 00
Latency at 24 12.8
hn(MPE)
Mean RR at 24 70.1± 0 .0 69.9:*:22.3 100,9 %44.5 0*0 I 95.1:t: 3.3
hrs (% baseline) 17.1
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3.6 Immunohistochemistry of Dynorphln Treated Rats Pretreated With
Dexmedetomidlne and Methoxamine.
~ to saline CXJOtroIs (no dynorphin, Figure 13-A) . there wa s a near
totar loss of CGRP-IR in the ventral hom of rats receiving saline + dynoI'phin
(Figll8 13-B). The few rema ining CGRP~R fibers \Wf8 p..nctate in appearance,
consistent with the severe motor dysfunction observed in these animals.
Oynorphin-induced neurotoxicity was restrided to spinal motor neurons . SP-IR
fibers in the dorsal hom of rats treated with sali ne + dynorphin (Fig ure 14-8 ) were
normal in appeara nce and ind istinqui shable from those in saline controls (Figure
14-A ).
Pretreatment with i.t, OX + MX, Ox. or MX (Figures 13-C. 0 and E,
respect ively) attenuated the neurotoxic effect of i.1. dynorphin. The number of
CGRP-IR neurons and the intensity of sta ining in the ventralhom were intermediate
between tha t of saline + saline and saline + dynorph in groups. These results are
consistent with the behavioural data for these groups (Table V) . SP- IR fibe rs in the
dorsal hom of dyn-pretreated rats trea ted with i.t. OX + MX. OX or MX were normal
in appearance and indisti nquishable from tho se in saline cont ro ls ( Figures 14-C,
0 , and E respectiv ely).
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Figure 13 Photomicrographs of calcitonin gene related peptide (CGRP)-
immunoreact ivity in motor neurons (L1 segment) in the ventral hom after the
intrathecal {i.t.} injection of saline (plate B), dexmedetomidine (10 1-19) +
methoxamine (10 1J9)(prate e), dexmedetomidine (10 IJQ) (plate 0 ) or methoxamine
(10 1J9)(plate E) followed 15 minutes later by the Lt. injectio n of dynorphin A (1-13)
(1931JQ, 120 nmol). Control rats (plate A) were pretreated with i.t. saline followed
15 minutes later by a second injection of i.t. saline . Rats were perfused 46 h after
the dynorphin injection . Scale bar = 100 um. Photomicrographs A and C-E were
prepared using TMAX (Kodak) film. Because of the severe toxicity with dynorphin
in group 8, photomicrograph B was prepa red using Technical Pan (Kodak) to
provide better contrast.
Ac
74
B
o
E
Figure 14 Photomicrographs of substance P (SP)-immu noreactivity in the dorsal
hom (L1 segment) of the rat spinal cord afte r the intrathecal (i .t.) injection of sal ine
(plale B), dexmedetomidine (10 ~g) + methoxamine (10 1-19) (plate Cl,
dexmedetomidine {10 IJg } (plate 0 ) or methoxamine (10 1-19) (pla te E) followed 15
minutes later by the i.t. injection of dynorph in A (1-13) (193 1-19, 120 nmol) . Control
rats (plate A) were pretreated with i.t . saline followed 15 minutes later by a second
injectIOnof it saline Rats were perfused 48 h after the dynorphin injection. Scale
bar =100 pm. All photographs were prepared using TMAX (Kodak) film
4.0 DISCUSSION
4.1 Metho xamine Poten tia tes Dexmede tom idin e-Induced Spinal
Anti noci ception
Intra theca l OX prod uced potent, dose-dependent antinocicepl:ion in both
therma l and medlanical nociceptive assays with E0soSof 0.044 and 0 .25 ~.
respectively. M doses So1 1J9, this effect was obsefved without behavioral evidence
r::A sedation or motor dysfunction. Qualitatively similar results wi th Lt OX have been
reported in the rat tail flick test (Fisher et al., 1991), as we ll as in other animal
species (i.e. dog ) using different nociceptive tests (i .e. the rmal skin t'witchrespo nse
Iatencyancl pawwrthdrawal to meenan ical pinch) (Sa bbe at al., 1994 ). These data
are cons isten t with the well recogn ized and select ive effect of i.t. az-agonists on
spina l noci ceptive transm iss ion (see review by Maze and Tra nquill i. 1991 ).
However, OX was found to be more potent in the present study. For
example. EDwS rang ing from 1.8 pg (0.2- 11.6 pg ) to 4.3 fJg (1.7 -10.8 IJQ) were
reported by Sabbe et at (1994 ) in the thermal skin twitch and paw withdrawal tests
in the dog . In the rat, Fisher at et (1991 ) observed that 3 or 10 1J9of i.t OX
increased hot plate and tail nick latencies to aJto ff value s (6 see) withi n 15 min.
An imals rece iving doses of 1 IJQdid not exhib it any significant antinocicep tion
compared to cootroI. Similar results were repoct ed by Ka lso et al . (199 1). Maximal
inaeases in the rat tail fl ick latency (S sec eut-off ~ 100% MPE ) were induced by i.t.
dose s of ~ 31J9. lottie rat hot plate (S2.S- C) test, Takano and Yaksh (199 1) fOUld
the EOS)(9S% CI) of l.t. OX to be 3.1 (0.50 - 17) !Jg, compa red to that of c10nidine
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and ST-91 with ED5Q's of 27 .6 (12-71 .3) and 5.3 (0.33-60.9) J.I9, res ped: ively. The
ord er of magnitude difference between the potency of OX in the TF assay in this
study and that of Kalsoetar. (199 1) and Fisher at al. (199 1) might be expla ined by
differences in instnmentation. apparent stimulus intensities (as reflected by the
base line latency) a"ld maxim..rn duration of exposure (as determ ined by the eut~
value) used to detennine the tail flick response. Factors such as radiant heat
temperatu res are known to sig nificantty affect baseline latency and the ob served
antinociceptive activity (I<a\wkita. 1987; d Amore et al., 1992 ). In the present study ,
all expermerts werecondudecl us ing the same instnment tXlder ind ent iCBI testing
conditio ns. Therefore, whi le differences exist in the absolute potency of OX
bet\wen these studies , the significant potentiation of OX by MX in the present study
is unlikely to be an art ifact of the experimenta l prot oco l.
The addition of a fixed dose of i.t MX (10 IJQ) significantly increased the
potency of Lt.OX as illustrated by the leftward shift in the dose-respons e curve.
This corresponded to a 5.5-fold and 25-fo1d increase it the potency of OX in the tail
flickand paw pressure tests . re spectively . Methoxamine was chosen for th is study
for two reasons. Firs t, it produced fewer mo tor effects in the spinal cord than
phenylephrine. Seoond,it has a slighUygreater a ,Jaz seHK:tivity ratio as dete rmined
by the displacement of fHlprazosin and [3H] p-am inodon idine from rat sp inal cor d
membraneS (Simmons and Jones , 1988 ). It is irrp:lrtanl to not e tha t a near-inactive
dose ofMX was used. By itself, MX (10 IJ9 i.t) yielded less than 5% MPE in the tail
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flick test and was completely inactive (0% MPE) in the paw pressure test. This
helped to min imize the unwanted motor effects induced by i.t. 01-agonists (Howe
at at, 1983; Yaksh, 1985), and to distinguish between a possible additive or supra-
additive interaction with DX2• The results obtained are consistent with: 1) a supra-
additive interaction between OX and MX; and b) a spinal site of action . Thus ,
pretreatment with either i.t.prazosln (2.51JQ)or Wyeth 27127 (0.5 ~gl significantly
attenuated the interaction between OX and MX confirming the involvement of both
major a-adrenoceptor subtypes and presumably the antinociceptive mechanisms
to 'Nhidl these two receptor subtypes are coupled. The failure of the low i.t. doses
of OX and MX (0.025 ~g OX + 10 ~g MX and 0.25 ~g OX + 10 ~g MXl , given l.v.,
to effect antinociception strongly suggests a spinal site of action . This conclusion
was further supported by the ability of low dose i.t. antagonists to blunt the
potentiation between i.t. OX and MX.
The mechanisms by which 02-agonists inhibit nociceptive transmission in the
spinal cord have been extensively investigated. For example , spinal 02-
adrenoceptors have been shown to inhibit glutamate release from the central
terminals of nociceptive primary afferent fibers in the rat (Ueda et al., 1995), and to
depress high threshold stimulus-evoked activity in nociceptive specific and/or wide
2 Isobolographic analysis is the preferred method for determining the nature
and magnitude of drug interactions but it requires a reliable estimate of the EOsoand
95% CI for each drug . Unfortunately, the motor dysfunction induced by i.t. o,-agonists
precludes an accurate determination of the ED5(J in behavioural tests of nociception.
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dynamic range neurons in the cat dorsal hom (Fleetwood -Walker at at . 1985;
Ornate at aI., 1991 ). Activation of neu'Ofla la~ors results in the open ing
of outwardly directed K"c:tIarnefs. This causes a hyperpolaiation of the cell , which
resul ts in the suppression of neuronal firing (Nakamura at al. , 1981; Egan at at .
1983). As well , a 2-adrenoceptor activation can inhibit voltage sensitive caldum
channels (Wi lliams and North, 1985), thereby suppressing Ca'" influx and the
fusion of neurotransmltter-filled vesicles with a synapnc membrane . These act ion s
on ion channels are bel ieved to be mediated through a G-prote in (Dunlap at at .
1987). As \W 1l, a oommon fean.re of all 0 2 adre nerg ic rece ptors is the ability, when
activated. to inhibit adenylate cyctase. This latter effect also appears to be
import ant in transme mbrane signaling .
In contras t, the mechanisrn(s) underl ying Q,...adrenoceptor med iated
antnociception is less dear. 0 l-Adrenoceptors have been shawn to regulate the
level of excitability of neurons rather than participating in the transmission of rapid
signals . Activat ion of Q 1-adrenoceptors s-creases intracellu lar concentra tions of
Oe" by several distinct mechanisms. The best understood involves the G-coup fed
act ivation of phospholipase C with the subsequent hydro lysis of two second
messengers - diacylg lycerol and inositol-1,4,5 triphosphate (IP)). The latter
compound stimulates release of intracellular Ca- which mediates a broa d range of
ce llular responses (Goodman and Gilman, 1990 ). As a l-adrenoceptors are
excitatory in the CNS (Aghajanian and Rogawski, 1983), the ability of a 1--a gonists
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to effect spinal antinocicept ion strongl y suggests that they activate , or at least
facilitate, an inhib itory neural input on primary afferent and/or projection neurons
in nociceptive pathways. Enkephalin-contain ing neurons are the most likely
candi date for this inhibitory neuron. Enkephalin, one of the three major
endogenous opioid peptides , is known to selectively modulate nociceptive
transm ission in the spinal cord (Yaksh. 1993). Additionally, enkephalin-containing
neur ons are present in a dense concentration within lamina I and II, which,
signifi cantly COITespond to the synaptic termination of nociceptive C fibers in the
spinal cord (Hunt at aI., 1980; Bresnahan et at, 1984). The well--demonstrated
potentiation of opioid spinal analges ia, including that mediated with enkepha lin
analogues, with a-agonists in both animal (Ossipov at at , 1990a; 199Ob; Ornate at
aI., 1991 ; Roerig et al., 1992) and human stud ies (Meisch at aI., 1990; Gordon et
at , 1992; Stddall et at , 1994) lend support to the possibility of an interaction
between 0l·adrenoceplors and enkephali n neurons in the modulatio n of
_ Indeed, Bautista(1996) has recently demJnslrated tha t Lt, NE. but not
Ox, exhibits aoss-tolerance to [L CA DL E (a a-selective opioid agonis t) in the rat,
implicating an spinal enkepha lin-dependent medlanism in Q 1-mediated
anitnociception. Overall , these results indicate tha t 0 1- and 02-adrenoceptors
utilize dist inct ant inociceptive mechanisms thereby fulfi lling a crit ical req uireme nt
for a supra-additive interaction.
Recen t molecular biologica l data point to the existence of multi ple subtypes
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of Q,- and Q 2-ad renoceptors (i.e . alA,IB-.d IC . Qv..2B,Md2C)(Bylund, 1985, 1988). In
this regard , phanna colog ical studies have shown that spinal ant inociception is
mediated by more than one a 2-adrenoceptor subtype . For example, Lt. OX appears
to effect antinociception through a"" receptors~ile the effects produced by ST-91
appear to be mediated by Q 28 receptors (Takano at at., 1992) . It was not the
intention of the present study to elucidate the specific receptor subtypes underlying
the anlinociceptive interaction . Of relevance to this discussion , however , is the
report that prazosin does exhibit antagonist activity at certain Q2-adrenoceplors
(a r ............·) (Takano and Yaksh , 1992) . However, this effect was observed at an i.t.
EOso dose of 381-19for ST·91 and doses exceed ing 100 1-19 for OX and clon idine
(Takano and Yaksh, 1992 ); doses 3 - 10 times greater than that used here . Wh ile
th is is admitted ly a relat ively small difference in absolute terms, the range of
effective doses that can be administered i.t. is limited. Regard less, the fact that we
are us ing a low dose of MX, a select ive 0 1-agonist not known to bind to °2-
adrenoceptors (Timmermans et al ., 1984) does suggest an interaction between
distind subtypes of 0 1- and 02-adrenoceptors. However, these data do not exclude
the possibility of an antinociceptive interaction between subtypes of the 0 2·
adrenoceptor. This remains to be explored .
While it is unknown if the supra-additi ve interaction observed in this study
also occurs in humans , these results suggest that there could be merit in using a
comb inat ion of °1• and <l:z -agonists for spinal analgesia. At the very least , this
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combination would allow a reduction in the analgesic dose of the Q2·agonist; an
important advantage given the marked bradycardia and hypotension that routinely
occur after the Lt. or epidural administration of 0 2-agonists (Pettinger , 1980;
Redmond, 1981; Virtanen , 1985) , Equally important is the potential for improved
analgesic effectiveness with such a combination. This effect might even be further
improved by the addition of a low dose opioid or other non-adrenergic analgesic
drug. The use of a long acting non-selective a-agonist, although more convenient,
is unlikely to be as effective as using a combination of 01- and Q 2-agonists. The
relative contribution of 01- and 02-activity would effect the nature of the analgesic
interaction. This factor would be extremely difficult to control using a single non-
selective agonist. These issues remain to be investigated and could be the subject
of future research .
4.2 Repeated Doses of Intrathecal OX, Alone and in Combination with MX,
Do Not Cause Spinal Neurotoxicity
In view of the safety issues related to spinal drug administration, the effect
of repeated i.t. injections of OX, alone and in combination with MX, on gross motor
function and spinal immunohistochemistry was investigated . This concern was
predicted on the following facts. DX is a potent vasoconstrictor. Coughlan et at.,
(1992) demonstrated dose-dependent constriction of dog middle cerebral arteries
(72.8 ± 5.7% of the maximal response induced by 40 mM KCI). Interestingly, the
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selective aractrener9ic antagon ist atipamezole only partia lly blocked th is effect at
OXconcentrations > 1Q"iM, suggesti ng some activation of o, -adrenergi c receptors.
Rat cerebral blood vesse ls contain post-jl..nctional a , -adrenoceptors that med iate
conlraction of vasccrar smooth muscle (McCullOCh and Edvins son. 1984).
Moreover, a l - and o , -adren oceptors cause vasoconstrict ion through inde pendent
ef'fe<::ta mechanisms (see Section 1.6); an import ant fact considering the poss ible
use ci a ,• and aragonist combi nations. The physio logica l relevance of this effect
is illustrated by the >45% reduction (p< 0.05) in cerebral blood flow induced by Ox.
with littl e or no effect on the cerelxal metabolic oxygen demand in anesthetiZed
dogs (Zomow at at , 1900). AI the spinal level, a-adrenoceptor agon ists decrease
SCBF in experimental animals by as much as 44 % (see Sectio n 1.6 ), and non-
adrenergic agents tha t cause a comparable reduction in SCBF are known to
produ ce sensory, autonomic and motor dysfu nction as well as histopathological
damage to spinalcord cells (seeSections1.4end 1.5). For example, i.t endothelin
(O.03 ~) induced comp lete motor paratysis with a marXed loss of CGRP-IR in
spinal moton eurons of the rat (Holdett at aI., 1989) . Fina lly, ce lls in the spinal
ventra l hom are especially sensitive toint~ in SCBF since the left and right
sides of the ventral grey matter are supplied by onl y one spinal artery (anterior
spin al artery) (Cousins and Bridenbaugh, 1988).
Twice daily injecti ons of i.t OX or OX + MX for fou- days produced no
beh avioral evidence of spina l neurotoxicity in the rat. Th us, rats exhibited normal
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posture. ga it and motor reflexes 2 h after the last (8th) injection of OX or DX +MX,
as compared to saline controls . Wh ile both treatments (10 IJOOX and 10 1J9OX +
10 IJ9 MX) p roduced severe sedation (1()()% MPE in the tail flick test and an
inab ility to pecform the rota-rod test) , animals completely recovered after eaCh
injecti on. The same doses . give n i.v.• yield ed a similar effect. These results, and
the fad that sedation is mediated supra-spinally, ind icate a vascular redistribution
of OX from the spinal cord . OX is hig hly lipophillic (Savcla at at , 1986) and
there fore is ab le to readily cros s blood brain barr ier.
Gross examination of the spinal cords from these animals revealed no
evid ence of inflammation, haemmorrhage or necro sis near l 1 (adjacent to the tip
of the catheter). Subsequent irmulohistoehemical staining revealed no detectable
change in either the patternor intensity of sp-and CGRP-IR in the dorsal hom of
OX or OX + MX treated rats as compared to the saline-trea ted controls . CGRP .IR
in motonet.mns in the ventral hom also rema ined lIld1anged from that of the saline
controls. In contrast, a single neurotoxic dose of i.t dynorphin produced
irreversible loss of the stepp ing and ta il flick reflexes. Gros s examina tion of the
sp inal cords from these rats revealed haemmocrhaging around the L1 segment
Although SP- and CGRP..fRfibers in the dorsal hom of rats treate d wi th dynorphin
we re no nnal in appearance and indistinquishable from those in saline controls,
there was a near total loss of CGR P-IR motor neurons. The few remain ing CG Rp·
IR fibers we re punctate in appearance, cons istent with the severe motor
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dysfunction. Intrathecal dynorphin is believed to cause neurotoxicity through a
deleterious vasoc:onstric:tiv effect (Long at at, 1987 ; Thomehill et at. 1989 ; Long
et at . 1994) cn:l thereforewas a St.itabIepositive control for this study. The results
with dyno rphin confinn our ability to detect spinal neurotoxicity following i.l drug
administration, and to localiz e the injury to a discrete reg ion and type of neuron.
Indeed. localized deaeases in CGRP-IR, reflecting damage to specific
CGRP<Onta ining neurons, have been Observed in the DRG and/or spina l corcI of
experimenta l anima ls foll owing dorsa l rhizotomy , (POhl at at, 1990), lumbar
sympathectany (Sekiguc::hiet aI., 1996), transection of the sciatic nerv e (Groves et
aI., 1996) , dYon ic constric:tioninjtsy or crushing of a peripheral nerve (Sommer and
Myers , 1995), or treatment with selected neur otoxins (capsaicin - Pohl at aI., 1990 ;
dspIati n - 'IM1itaker-Azmitia at at , 1995). Similar changes in spinal CGRP-IR have
been reported in humans who susta ined traumatic spinal cord injury (Melinak et at,
1994). Thus , CGRP-IR has been used as an immunohistochemical marker of
neuropa thy and neurotoxicity arising from a range of insu lts. Of relevance to the
present study is the reported decrease in CGRP-IR in spinal motoneu rons after
local vasoconstrictive injury (HOkfett et al., 1989).
To assess pos sible neurotoxic injury to prima ry afferent terminals in the
dorsa l hom, change s in both SP-IR and CGRP-IR were examined . However, as
SP·IR sensory fibers have been demonstra ted, in vffro, to be more senstitive to
capsaicin tha n CGRp·I R sensory fibers (Jeftin ija et et.. 1992) , SP-IR was chosen
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as the primary marker to examine the potential netrOtoxicity of a-agonists to
primary afferen t fibers . Substance P is a undecapeptide that is dense ly local ized
in the superficial laminae of the dorsal hom of the spinal cord (Moctlland. 1982) ,
specifICally in sma ll diameter sensory afferent fibers (HOkfelt at 81., 1975 , Hunt,
198 3 ). Substance P levels in the dorsa l hom are drama tically red uced followi ng
dorsal root rhizotomy (Pool et at. 1990) . unilateral dorsal root gangl ionectomy
(HooNeet al., 1981) or 9xpo$lX8 to the select ive neurotoxin. capsa icin (Nagy et at,
1983; Pool at al.. 1990) changes that correlate with dist urbances in nociception
(Ah elli et a t.,1993). CGRP is also present in sma ll diameter primary afferent fibers
and, like SP, is depleted from these fibers by pretreatment with capsaicin (Pohl et
ai , 1990 ). Thus. injury to small diameter primary afferent fibers by sub-acute
adm inistration of a-agonists shOuld have been detectable using these
immunohistoch emical markers .
The absence d toxicity in th is study wa s not due to problems of spinal drug
delivery. Indeed. antinociception and motor function were assessed after each
dose confi rmin g effective drug administration and consistent phannacologica l
activity throughout the treatment schedule. Add itiona lly , there appeared to be an
absence of significant to lerance to the multip le injedions of OX and OX + MX.
There was a modest reduction in the time course of motor effects (rota-rod test) but
the apparent magnitude of ant inociception rema ined unchanged. However, the
dose of OX used in the net..roI oxicity study exceeded 100% MPE in the tail fl ick test
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thereby limitingthe detection of toIenn::e on the basis of magnitude. The apparent
lack of tolerance in this study is in agreement with a recent study by Hayashi at at
(1995). Mer seven days fAcontinuous subc:ulaleous infusion of Ox. the analgesic
response to a'I media'l effective dose or OX in the tail fl ick test remained unaltered
compared to that of saline-infused rats. Thus, the absence of pharmacodynamic
tolerance to twice da ity injecti ons of II OXfor fou' days in the present study is not
surprising .
Drug dose is a critical factor in any neurot oxicity study . There were no
plblished neurotoxicity data for a-agonists (see Section 1.6) from which to se lect
a dose of Lt, OX for this stud y. Exposure of experimental animals to toxic agents
in high doses is a necessary and valid method of discovering possi ble hazards in
tunans(Klaassen, 1995). Therefore, a dosed 10~. equivalent to 100 time s the
ED5Q in the tailflick test. and 25 timesthe ED5Q in the paw pressure test, was used.
Th is satisfied the requ iremen t for a high dose while remai ning with in a rea listic
range of din ical analgesic doses of l.t, cIon tdine (calculated per kg of body weigh t)
(Racle at al., 1988). Of cour se, the absence ottoxicity at 10 1J9does not exclud e
its possibility at higler doses. H<M'eVel',!he latter'MJUk:! certa inly exceed the upper
range for d inica l ana lges ia of a-agonists and so the rele vance of such stud ies
would be questionable. Since it was not our intention to asess the safety of i.t. MX
per sa, but rather to investi gate the safety of a threshold dose of MX ceHnjected
with i.t. Ox, the dose of MX in the neurotoxicity study remained unchanged at 10
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~. The absence of toxicity with th is combination suggests that the co-activation of
a 1- and a 2-adrenoce ptors, at least at the se doses , doe s not exceed a threshold for
vasocontridion-induced spinall'lElU'Otoxicity in the rat
4.3 Pretreatment With Intrathecal OX, MX and OX + MX Protects Against
Oynorphin-lnduced Spinal Neurotoxicity
The demonstrated lack of neurotoxicity with i.t OX and MX in this animal
model raised an important issue; namely the safety of these a -agonists in
combination with a drug known to adverse ly affect SCBF and neuronal viabil ity .
Thus . the influence of l.t, OX and MX on a netXOtoxic dose of i.t . dynorphin was
investigated using the same behaviora l and immuno histoche mical indices as used
in OX and MX neurotoxicity study .
In saline pretreated rats, l.t dynl::ltphin resulted in a permanent loss of the tail
flick and stepping reflexes, permanent hindlimb para lysis rendering the rats unable
to pertorm the rota-rod test, and marked cel!Uar necrosis in the ventra l hom. These
resu lts were identical to those observed in the OX and MX neuro toxicity study. In
contrast, pretreatment with U. Ox. MX or DX+MX significantl y attenuated the
netrOtoxic effect of dynorphin. All four rats receivi ng the DX+MX combi nati on.
three of the five rece iving OX and three of fOlx rece iving MX had a normal stepp ing
reflex and normal gait, 24 h after dynorphin. In those anima ls exhibiti ng protection
from dynorphin toxicity, their 24 h rotCHOd scores were only marg inally below their
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baseline values and sign ificantly different fran those of the sal ine-<:lynorphin group .
A sirniIa"trend was observ ed with the tai l flick refle x. Invnunohistoc:hemiealfy. the
n..mber of CGRP-IR neurons and the intens ity of staining in the ventral hOm IN9f8
intermediate between that of the saline+saUne and saline+dynorphin groups .
CGRP - and SP-IR in the dorsal horn was equivalent among all the treatment
gn:><.ps. ThJs. rather !han exacertlating the neu-otoxicity. pre-treatment,.;tI! i.t, OX
and/or MXblunted the insult infl ld ed by l.t, dynorphi n up to 48 h after injection.
In view of the werr-estab lished effect of a-agonists on vasculer smooth
musde, there was a real poss ibil ity that i.t, OX and MX might augment the
vasoconstrictiv and thus net.I'Otoxic effect d l.t. dynorphin. Therefore , an attempt
was made to identify a threshold dose of dynorphin that would induce minimal but
detectable nesxotoxici ty . In a preliminary dose-response experiment. 60 nmof (96
JJ9) failed to produce any behaviou'al or immunohistochemical evidence of toxicity .
The 80 (128 1JQ) dose produeecl transient hindli mb paral ys is. revers ible loss of the
tail flick reflexbut no histopathological evidence of spinal toxicity. The 100 (160 ~g)
dose resu lted in hi nd limb dyfuncti on that lasted up to the time of perfusion (48 h),
irreversible loss of the tail flick reflex but still no imunoh istochemi ca t evidence of
toxicity . At a dose of 120 nmol (193 ~). i.l dynorphin resu lted in para lysis that
persisted up to the time of perfusion 48 h later, irreversib le loss of the stepping and
tail fl ick reflexes and an attenuation exCGRP-lR neurons in the vernal hom. These
data ind icate the absence of a distinct dose-respon se relationship using both
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beh avioral and immunohistochemical indices. Rather . dynorphi n neurotoxicity
appears to be an all-or-nale phenomenon, consistent with the proposed
rnedlanism(s) underlying this outcome (see section 4 .5).
4.4 Absence of Neurotoxicity With tntrathecal OX and MX
There are several possible explanations that migh t account for the absence
d spinal neurotoxicity with these potent vasoconstridors. One is that the c:legree of
vasoconstriction induced by i.t, OX and MX was not sufficient to trigger the
secondary events that under1y neurotoxicity. The threshold decr ease in SCBF
(eXl:entldlration) requ ired to el icit spinal neurotoxicity has not yet been defined in
hemodynamic stud ies . In studies of cerebra l blood flow , it has been suggested tha t
any perifocal tissue with a blood flow of <50% of control is at risk of injury/death
(SiesjO, 1992a). However. these resuttsare based on short term (1 -7 day) studies.
As~ in Section 1.6, anti l'lClciceptive doses of i.l a--agon ists decrease SCBF
by up 1039%; an effect lasl ing for up to 45 min (Gordh at al. , 1986a; Crosb y at al .
1990) . These changes are comparable in magnitude to those caused by neurotoxic
doses of Lt, dynorphin and' suggest that the ventral spinal cord may be more
sens itive to deaeases in SCBF than either the dorsa l spinal cord or ce rebral tissue .
A1tematively . a-agonists could bene fi t from physiological compensatory
mechanisms (autoregu lation of blOOdflOoN) andfor cono.m-ent pharmacological
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effects (hypothemria, dired. inhibition d net.n:naI ae:tivily) that preven t the metabolic
disturbances lead ing to ischemic cell death . Cerebra l and spina l blood vessels
have the inher ent capa ci ty to regulate blood flow in the face of cha nging arterial
blood pressu-e (West, 1985 ). This phenomenon is known as autoregulation. In the
ra t, autoregulation of SCBF occurs between 60 to 120 rrvn Hg (me an arteri al
pressure ) (Hickey at at , 1986). Th is is consistent with autoregulation of cerebra l
blood flow in the range of 70 10 150mn Hg (Rape Ia andQeen, 1964 ; Agna li at aI.,
1968; Str3ndgaard at aI., 1974 ; Hem8ndez-Perezet at, 197 5). As a resutt, loca l
autoregulatory mech an isms cou ld compensate fo r a -agon ist induced changes in
vascne- tone, thereby mainta ining adequate tissue perfusion and cell homeostasis.
The two most ob vious pharmacological effects of Qz-agon ists that wou ld
prevent ischemic injury are : a) hypo thermia ; and b) direct ne uronal inhibition . The
influence of temperature on ischemic brain injury and the protective effect of
hypothennia are well recogn ized (see revi ew by Colbolme at aI., 1997). For
example . brief post -ischemie decreases of 3-4 ·C (rectal temperature) in the gerbil
yielded histological evidence of cerebral protection in the CA1 region of the
hippocampus up to 7 days post-.fschemia (Buchan and Pulsinelli, 1990; Chopp et
at . 1991). Of relevance to the present Studyis the well knoYm neuroprotective
effectof mild to moderate intra-isdle mic hypothermia (Busto et at , 1987; Chopp et
aI., 1989; Minamisawa et at, 199Oa,b; Welsh et 81.• 1990; fwal et at , 1993).
Indeed. intra-.fschemic hypothermia (3Q· C brain temperature ) unequivocally
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pro tected neurons in the CA1 region of the gerbil on the bas is of behaviora l,
physioIogic:aIand histologtca l endpoints (Nc.ne and Cor'bett, 1994 ). Protect ion was
still evident 3 weeks after carotid artery occlusion (Nur.oe and Corbett, 1994) . Using
histological indas, Dietrich e t at (1993) reported signifICant net.ropfOtection with
intra -i scb emic hypothermia for up to two months in the rat In a similar study,
permanent neuroprotedion was reported in the rat using a battery of behavioral and
fI.n::liona l tests (Green et at, 1992 ). In this regard. the systemic adm inistra tion of
a 2-agonists has been shown to cause dose-dependent hypothermia in rodentS
(Mino r at a l..198 9; Menon at al., 1990; MacDonald et at. 1991 ). Decreas es in
rect al temperature ranged from 3-6 -C and pers isted for up to 3 h after inject ion .
That this effect is centrally mediated is indicated by the fa ilure of the peripherally-
select ive a 2· antagon ist, L-659,066 to block i.p. d onidine-induced hypotherm ia
(Menon et at , 1990) . In the pre sent study. Lt. OX, alone and in combina tion with
MX, decreased rectalt~ by 3.4 :t O.3 · C and 3 .3 :t O.4·C, respectively tOt"
up to 4 h. Such terrtpE!l"'ab.Xchanges should be sufficient to attenuate any adverse
vaso constrictive effects induced by the peri spina l administration of a -agonjsts,
based on the neuroprotective effect of intra- and post-isehemic hypothermia in
animal models of global ischemia
In the eNS , the activat ion of a radrenoceptors hyperpolarizes the cells upon
which they reside, thereby irtlibrting voltage sensitive caa.m channels, ea- influx,
and neu'Ofl3t fimg (see Section 4.1). That an elev ation in cytosolic ca lcium during
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ischemi a contributes to cell injury is v.oell recogniZed (Cho i et at , 199Oa.b; SiesfO.
1992a,b). Therefore , attenuat ion of this calcium overload wou ld be expected to
ameliorate I"lEU'a'l3I ifluy. TIle activ ation of a 2.-adrenoceptors has been shown to
irtlibit calcium conductance in neurons (Dunlap and Fid'tlach. 1981 ; Lipsoomb et
at , 1989; Boehm and Huck. 199 1), and to decrease the duration of the calcium-
dependent action potentia ls in vitrO (Dunlap and Fid'lbach . 1981; Canfteld and
Dun lap, 1984). Of relevance to the present study is the report by Bickler and
Han sen (1996) that the a 2-agonists, mivazer ol (1 IJM) and clonidine (0.1 \.1M) ,
sign ificantly inhibited the earty rise in cytoso l ie calcium concentration in rat
h ippocampal brain slices evoked by glutamate (3 mM) during hypoxia; conditio ns
used to mimic those of ischemia. Mivazerol and c10nidine also decreased
glutamate release and cellular damage as assessed by leakage of lactate
dehydrogenase. In an in livo study, the i.p. administration of 10 and 100 lJg/kg OX
reduced the infarct size in a rat model of incom plete cerebra l ischemia (Hoffma n at
a t, 1991b). Normal bra in temperature (3r C) was mainta ined throughout the
experi ment thereby exduding hypot hermia-med iated neuroprotedion and a
supporting a role tee direct Q 2..mediated neuronal inhibition. 'These resu lts. and
those of the present study indicate that a 2-adrenerg ;c agonists elicit at least t'NO
concu rrent pharmaco logical effects that are capable of offsetting adve rse
hemodynamic changes in the eNS .
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• •5 Mechanisms of Oynorph ln-tnduced Spi nal Neurotoxicity
The necrosis arising from the spina l inject ion of dynofphin doe s not appear
to be a direct toxic effect of the drug . Add ition of dynorphin to cul tured spinal cord
neurons (yiefding a final concentration of up to 1 mM) did not alter cell viabi lity
(Long at al., 1994 ). Rather , dynorphin neurotoxicity appears to result from drug-
induced spinal cord ischemia. Using radiolabel1ed microspheres, Long at al. (1987)
reported a dose-related decrease in rat sceF 10 min after the i.t injection of
dynorph in A (1-13). The geatest reduclial oc:cured in the spinal segments d osest
to the tip of the i.t, cathe ter (lumbosacral , 37·75% and thoracic , 38%) . In a similar
study, 2OmlOl al i.t dynctphi n A {1-13) signiftcantJydeaeased SCBF (up to 50%)
in segments 2 an caudal and 1 an rostra l to the tip c:J the catheter (Thomehillet et.
1989) . These hemodyna mic changes were temporally associa ted with a 2.6-2.8
fold increase in lactate concentration in the spinal CSF (Long at al., 1994),
indicativeof an increase i'1anaerobi c metabolism. Interestingly. c::eradministration
of the vasod ilator hydralazine reducecIthe elevation in ladic acid conce ntration and
elim inated the paralytic and neuropathological effed. of dynorphin A (Long et at ,
1994).
A sustai ned imbalance betwee n blood flow and metabo lic demand in the
eNS elici ts a cascade of events that results in cell death . One of these events is
the accumulation of excitatory amino acids in the extracellular flu id. The CSF
ooncentration of glutamate increased 4-foId (6.4 IJM) and aspartate 3-fo ld (6.3 IJM)
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in rat sp ina l cord folloNing a neurotoxic dose (20 or 40 nmoI) of i.t dynorphin A
(Long at at . 1994). Thi s increase was not due to the proteo lysis of exoge nous
dynorphin as g1utanate is not a CXII"lStitl..Jof this peptide. Even if it were , a 20-40
nmoI dose of dynorph in A wou ld not yield a concentra tion of glutamate in the ~
range, a conserv ative estimate at best. Dynorphin could enhance the relea se of
EMs by a direct interact ion with presynaptic neurons and/or as a resul t of local
ischemia caused by dynorpin-induced vasoconstriction . However, the extracellular
ooncentra tion of glutamate and aspartate remained unchanged in spinal cord cell
cultures exposed to 100 and 500 ~M of dynOfphin A (long at at . 1994) . These
results ind icate tha t exposure to dynorphin in vivo. but not in vitro, triggers the
release of EMs thereby suggesting that accumulation is an ische mic-r e lated event
Excitatory amino acids have been implicat ed in many forms of spinal cord
injuryttTOughtheir activationof N-meth yf· D-aspartate(NMOA) receptors (Meldrum
and Garthwaite. 1990; Long et at , 1994 ). 1nthis regard , the motor dysfu nction and
neuropathology induced by i.t dynorphin appears to be mediated, at least in part.
by NMDA-recep tors. This is indicated by the long term protective effect afforded by
a series of~ and non-a:mpetitive NMOM'eceptor antagonists (ketamine.
dextromethorphan or MK-801 ) aga inst dynorphin toxicity in the ral None of these
antagonists altered the etrect of i.t, dynorphin on lumbosacra l bloo d flow or the
subsequent increase in lactic acid concentration. Thus , in the absence of any
temperab.Xe c:hange (body temperature was not monitored by Long at el. , 1994), the
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nelrC!pl'Otective effect is best explained by the blockade of NMOA-receptors whose
excessive activa tion by EMs elicits secondary pathophysiological event s. The
bind ing d EM's to NMOA-receptors causes a rise in intracellular calcil.•m and
sodium (Vomow and Coyle , 1991 ; see section 1.5) . Such a change would dearly
aggravat e an already unstable condition initiated by ischemia (i.e. ATP depkrtion,
degradation d macromoledues important to membrane and cytoskeletal integ rity ,
production of metabo lic acids ) leading to cellular edema and lysis .
There are three other poss itHe ways by wh tch dynorphin may effect
neurotoxicity via the NMDA-receptor-channel complex. Oynorphin maybind to a
site on the c:omplex to increase EM binding at the NMDA receptor (i .e. an allost eric
effect) thereby opening the ion c:hamel. In fact . dynorphin has been shown to
enhance the binding of the NMOA-selective ligand (['H]CGP-39653) to rat bra in
merTtlranes in vitro(Ounont ard Lemaire, 1994). If a cxmparabIe effect occurswith
glutamate/aspartate in vivo, dynorphin would not on ly lead to the accumulat ion of
EAAs, but'MJUldalso enhan:::e their binding to the NMDA-receptor (and presumably
their abil ity to open the ion cha nnel). Alternativel y, dynorphin may facilitate the
opening of the channe l by binding dir ectly to the NMDA receptor. Topica l
app lication of dynorphin to the spina l cord pote nt iated a C-fi ber evoked , NMDA~
mediated refle x in the rat (Caud le and Isaac, 1988). This effect is known to
precede: a) the permanent loss of thi s reflex (Caudle and Isaa c. 1988 ): b) motor
paralysis (Skilling et at . 1992); and c) the extracellular eccumctatlcn of EMs
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(Skilling et el., 1992) induced by dynorphin . Given that dynorphi n At.1:J is also
known to d isplace L~Hl glutamate bind ing from rat cortical membra nes in vitro
(Masscwdier and Hunt, 1989) , theSe resufts are consistent with a direct interaction
of dynorphin at the NMOA-receptor. Lastly . dynorph in may facilitate channel
opening by btnd ing to a separate non-opioid (PC P1) site on the NMDA..f8Ceptor ion
d'lann ef complex. Fragments of dynorp hin (e.g. A,.n) that do not bind to K-opioid
receptors induce NMDA-sensitivespinal l18U'Ol:oxicity in the ra t (Bakshi and Faden.
1990). Although thesereeunsdo not differentiate between NMOA- versus other
non -opioid sites on the complex, in vftro binding data support an interadi on
between dynorphin and the PCP receptor (Shukla at aI., 1992). The relevance of
these data to dynorph in toxicity is supported by the observation that metaph it, a
PCP receptor antagonist, blocked the motor dysfunction induced by dynofphin
(Shukla et al., 1992). These possible interactions are illustrated in Ftgure 15.
In summary , current evidence sug gest s that the pathophysiolog ical effects
triggered by It, dynorpt'in are related to some modu lation of spinal NMDA recep tor
activity . However. the nature of the interacti on between dynorph in and the NMDA-
receptor ion dlameI comp lex, and thus the precise mechanism(s) of neurotoxicity
have not yet been determined .
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presynaptic
nerveterminal
postsynaptic
neurone
Fig ure 15 Possible mechanisms of action of dynorphin on the NMDA receptor
complex. The facilitatory effects of dynorphin A and related peptides on NMDA
receptor-mediated activity may be due to a direct interaction of the peptide with the
receptor complex. Oynorphin was found to intera ct with both phe nycyclidine (PCP)
and NMDA receptors on the postsynaptic neuron . Oynorphin may also enhance the
release of glutamate Bither by a direct interaction with presynaptic neurons or as
a result of local ischemia caused by the constrict ion of small blood vessels. EAA.
excita tory amino acids . (Sou rce: Figure 2. Shukla and Lema ire , 1994)
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4.6 Possib le Neuroprotective Mechanisms of I.t. OX and MX Ag ainst
Oynorphin~nduced Spinal Neurotoxicity
Although i.t OX and MX proved free of neurotoxicity when given alone (see
section 4.4), there was concem that these drugs, as vasoconstrictors, might
exacerbate the neurotoxic effect of i.t dynorphin. Surpri singly, pretrea tment with
i.t. OX and/or MX provided functional and histological protection for up 48 h after
i.t dynorphin. The mechanisms by which OX and MX might ameliorate Lt,
dynorphin toxicity may or may not be the same as those respo nsible for the
apparent safety of these drugs when given alone (autoregulation of blood flow,
hypothennia, hyperpolarization - see sectton 4.4) .
Normal autoregulatory mech ani sms are clearly overwhelmed by l.t.
dynorphin A sustained decrease in SCBF and the aa:unJIation fA lactate acid and
excitatory amino acids in spinal CSF have been consistently observed in l.t,
dynorphin-trealed animals (see section 4.5). As vasoconstrictors, c-aqoniste wo uld
be expe cted to place additional stress on th is compensatory process. Thus,
autoregulation of blood flow is unlikely to play a ro le in the neuroprotective effect
of a-agonists.
4.6.1 Hypo thermia
Hypothermia, a side--effed of Q:-agonist admin istration , is a poss ible
mechanism for the Q:-agonist mediated neuroprotection from dynorphin toxicity
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(see sedion 4 .4). a.,-Agonists induce hypoIhen'nia in rodents by ahering peripheral
blood flow and by deaeasing non-shivering thermogenesis (loPachin and Rudy,
1983). These effects are centrally mediated. In the present study, l.t, OX and OX
+ MX deaeased rectal temperature by 3.4 ± O.3· C and 3.3 t O.4 · C. respectively.
The neuroprotective effect of hypothermia is we ll recog nized (section 4.4) and has
been used dinically for spinal con::I protection dl.rilg aortic occlusion (Pontius et at .
1954 ) and following spinal surgery (Albin et at. 1968 ). The precise mech anisms
under lying this neuropro tedion are un known . Howe ver, hypotherm ia has been
shr:rNnto: a) inaea se SCBF by 24-37% in pentobarbital anesthetized rats (twai at
al ., 199 1); b) decrease glutama te and aspa rtate release in the peri- an d/or post -
ischemic period (Globus at aI., 1988; Busto at at . 1989; Baker at aI., 1992); 0)
reduce metabol ic activity, thereby decrea sing the rate d ATP depl elion and the
associated accum ulation d inorganic phosphate and lactic acid (Sutton at at., 1991 ;
Yager and Asselin, 1996); d) imi bit certa in intracellular ca lcil.m-activated enzymes
such as lipases and proteases ; and e) preserve the activity of other calcium-
dependent enzyme systems (e.g. ca lci um/cal modu lin dependent pro tein kine ses,
protein kinase C) (Simon et at . 1984; Verna tsu et 81., 1988 ; ChlXn et at, 1990a ;
1990b ; Cardell et aI., 1991 ; Scheinberg, 1991) and the synthesis of ub iqu itin , an
impo rta nt factor in the dispos al of prot eins ar ising from hypoxia and ische mia
(Yamashita et at , 1991 ). All these effects wou ld serve to protect cells from
ischemic injury .
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4.6.2 Hype~ariz.ation
Direct.inhibition of neuronal adiv ity is also a possible mechanism by which
az-agon ists mayprotect against dynorphin toxicity . The pharmacological activation
d presynaptica~orshas been found to inh ibit the release of excitatory
amin o acids in rat spinal cord slice s (Ueda at at. 1995) by inh ibiti ng voltage
sensitive ea- c::hamels (Wi lliams and North, 1985) . Thus , co-adm inistrat ion of OX
with dynorphin would be expected to inh ibit the release of EM. tha t is known to
occur with dynorphin-induced ischemia. Post-synaptica lly. a 2-adrenoceptors
hypefpolcrize cells by opening outwardly directed K"'channe ls (Wi lliams and North,
1985) . Both of these effects would serve to attenuate the potentially ca tastrophic
influx of Na· and Ca" evoked by the ac:a.mulation of glutamate and aspartate (see
section 4.4).
Stimulation of presynapticaradrenoceptors by OX has also been shown to
jnhibit catecholamine release (Johansson and Etrenstrom, 1988) . Duri ng cerebral
ische mia, there is ina-eased release of norepinephrine and dopamine (Globus at
at , 1988; Globuset aI., 1969 ; Gustafson at at, 199 1), and NE, applied topical ly to
the eNS . has a direct toxic effect on cortical neurons (Ste in and Creccc, 1982). If
the ischem ia induced by i.t. dynorphin triggers a toxic release of catecholamines ,
the n OX wou ld be expected to attenuate both the release and the associated
toxici ty. Pretreatment wTth i.p. OX (30 min before carotid artery ligati on and
he morrhagic hypotension) improved neurologica l outco me in the rat, and
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dec-eased plasma catedlolamine concentration in a dose-dependent manne r
(Hoffma n at aI., 1991b). This neuroprotective effect was blocked by c0-
admi nistration of atipamezole. an Qz-adrenerg ic antagonist Posti sche mic
administrat ion of OX(to min after arterial occlusion) also had a protect ive effect in
a rabbit model of focal cerebral isdlemia however the re levant receptors were not
identified in this study (Maier et al., 1993 ).
4.6.3 lmidazoline Receptor Mechanism(s)
The neuroprotective effect of OXcould be media ted by rece ptors oth er than
those of the Qz-subtype . Hoffman and colleagues (199 1a,b) demonstra ted that
pretreatment with i.v. d onidine or i.p . OX improves the neurolog ic outcome in rats
SlJbieded to incomplete globa l ischemia , an effect repl icated by the a;r-antagonist.
idazoxan (Gustafson at at , 1989; 1900). This apparent paradox could be
reconciled by the fad that idazoxan, clonidine and OX have affi nity for the
imidazole-preferring receptor . Moreover. activation of th is non-adrenergic receptor
has bee n shown to exert a protect ive effect against focal cerebral isch emia in the
rat (Mai ese et at, 1992). Intere stingly. the selecti ve nOrHmidazole az-a ntagonist
SKF 86466 did not protect aga inst ische mia (Ma iese et at , 1992 ). The imidazole
receptor complex is indeed fundionally coupled as demonstrated by the
hypotension evoked by the binding of c1onicline, idazoxan or rilmen id ine to
imidazole rece ptors in the RVLM (Reis et et., 1992). (' HI Dexmede tom idine has
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also been shown to bin::J to a nove l imidazole binding site i'1 !he a:iJft rat spinal CXll"d
(s av cra and Savoia , 1996) . Thus . the imidazole-prefening recep tor , and not a 2-
adrenoceptors, may elicit the neuroprctedive effect of OX and OX+MX in the spinal
COfd.
The exact mechani sms undertyi ng the neu roprotedive effect are unknown
but at least two possibilities exist. Imidazole compounds such as 1-(2-
trifl uoromelhylphenyf) imidalzole (TR IM) have been shown to inhi bit mouse
cerebellar neuronal nitric oxide synthase (NOS) activ ity in VJtro (IC511 = 0.32
~M)(Handy at aI., 1996; Handy and Moore, 1997). Under the experimental
conditionsused, TRIM appeared to (X)fl'lpete with the substrate L-arg inine for NOS.
This observa tion could be importa nt giv en the putat ive role of NO in neurotoxicity
following excessive NMDA receptor activation (Dawson at at , 1991 ,1993) and the
demonstrated neuroprotedive effect of NOS inhibition (Maiese at aI., 1997).
Alternatively, imidazo le compounds activating mitochondrial 12 receptors in
astrocytes may reduce Ca" uptake into neurons by stimulating the up take of Ca-
into astrocytes (Reis et al., 1994). The deleterious effects of lCa' are summarized
in sect ion 1.5.
4.6.4 Po s sible Neuroprotective Mechanisms of MX
Unli ke the protection afforded by pretreatment with OX and OX+MX, the
nElU'OpCOl:ect ion observed with MX aga inst dynorphin's spina l toxicity is surpri sing
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and difficu lt to explain MX is an a, ·seledive adre nocepror agon ist (S immons and
Jone s. 1988) with a predominan tly depolarizing effect on neurons . Thu s, direct
post -synaptic I'lelXOOaI mibitial as induced by a 2-agon ists cannot account for the
protective effect of MX. However , indirect inhibition seconda ry to the facilitation of
other irilibitory inputs (e.g. enkephalinergic inhibition) by MX is possi bl e. Indeed ,
i.l MX-induced faci litation of spina l enkephalinergic inputs has been imp licated in
the po ten tia tion of OX antinocieption (see sect ion 4.1: Loom is at al ., 1992a .b ).
Sucha facilitatia'l COlAdmoc1JIatethe toxic relea se of excitatory amino aci ds in the
spinal cord . The activation of jJI~-opioid receptors by enkephalin has also been
shcPNnto hyperpolarize I"leI.I'alS in the Slbstantia gelabnosa c:A rat spinal cord slices
(Yoshimura and North , 1983) .
The central administra tion of MX does not reduce body tempe rature in
experi mental animals (see ReSUltS). Thu s. MX lacks a puta tive and presumably
important neuroprotect ive feature of Ox. In addition, drugs lack ing an imidazole
moiety like MX have extremely ION affinities for the ~-imidazole receptor (Hosseini
et at . 1997). This observation argues against a non-adrene rgic imidazole-mediated
neuropro tedive effect like that attribut ed to ai-agonists like p x,
As introduced in Section 1.5, the metabolic consequences of ische mia are
m,m erous and comple x. Thus , the amelioration of dynorphin toxicity by MX could
OCW" atcneormoredthesecondaryevents aris ing from iSChemia (see Figure 2) .
To our knowledge. th is is the firs t report describ ing a neuroprotect ive effed with
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centra lly administered a ,-agonists. The resu lts provide no infonnation about the
mechanism(s) underlyi ng this effect and there is a paucity of information in the
literature to account for such a result Before deta iled medlanistic studies are
Lndertaken . it will be necessary to test the effects of MX and other a ,-agonists in
selected animal models of ischemia. These experiments would determine: 1) the
durati on of neuroprotection afforded by these chJgs ; 2) if the neuropfOteclion is
lI'liq.Je to i.t dynorphin or if it is effective against general ischemic injury; and 3) if
the neuroprotective effect extends to all a ,-agonists with diffe ring physicochemica l
properties . Given the mJ ltitude d potential sites of action of MX, the elucidation of
the exact mechanism(s} is likely to involve a significant investment of time and
resources .
4.TSummary
The results of the present study raise a runber d other important questions.
Is the d Lration of l'leI.XOprOtec6on affa'decI by a-agonists permanent or do they only
delay the developmen t of neurotoxicity? How soon must these drugs be given after
dynorphin to modify the toxicity? 'Nhat is their spectrum of ad ivity against other
forms of ischemic insult? VVhat are the relative contributions of direct inhibitory
versus indirect hypo themic effect s of Q 2-agonists in preserving neu rona l function?
Add it iona lly , doe s the lack of neurotoxici ty extend to other speci es, tncIuding
humans? Answers to these question could pro vide important cl ues to the des ign
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of other neuroprotedive agents, or combinations of agents in the treatment of
ischemic iI'1lIY. AI.the very least, the resutts cI this study provides furthef evidence
for the safety cI It, a-.agonists using an a-limal model that is vulnerable to ischemic
inju ry in the spinal cord , and for their potential use as neuroprotective age nts .
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